The Staphylococcus aureus Response to Unsaturated Long Chain Free Fatty Acids: Survival Mechanisms and Virulence Implications by Kenny, John G. et al.
The Staphylococcus aureus Response to Unsaturated
Long Chain Free Fatty Acids: Survival Mechanisms and
Virulence Implications
John G. Kenny
1, Deborah Ward
1, Elisabet Josefsson
2, Ing-Marie Jonsson
2, Jason Hinds
3, Huw H. Rees
1,
Jodi A. Lindsay
3, Andrej Tarkowski
2, Malcolm J. Horsburgh
1*
1School of Biological Sciences, University of Liverpool, Liverpool, United Kingdom, 2Department of Rheumatology and Inflammation Research, University of Gothenburg,
Go ¨teborg, Sweden, 3Division of Cellular & Molecular Medicine, St George’s, University of London, London, United Kingdom
Abstract
Staphylococcus aureus is an important human commensal and opportunistic pathogen responsible for a wide range of
infections. Long chain unsaturated free fatty acids represent a barrier to colonisation and infection by S. aureus and act as an
antimicrobial component of the innate immune system where they are found on epithelial surfaces and in abscesses.
Despite many contradictory reports, the precise anti-staphylococcal mode of action of free fatty acids remains
undetermined. In this study, transcriptional (microarrays and qRT-PCR) and translational (proteomics) analyses were
applied to ascertain the response of S. aureus to a range of free fatty acids. An increase in expression of the s
B and CtsR
stress response regulons was observed. This included increased expression of genes associated with staphyloxanthin
synthesis, which has been linked to membrane stabilisation. Similarly, up-regulation of genes involved in capsule formation
was recorded as were significant changes in the expression of genes associated with peptidoglycan synthesis and
regulation. Overall, alterations were recorded predominantly in pathways involved in cellular energetics. In addition,
sensitivity to linoleic acid of a range of defined (sigB, arcA, sasF, sarA, agr, crtM) and transposon-derived mutants (vraE,
SAR2632) was determined. Taken together, these data indicate a common mode of action for long chain unsaturated fatty
acids that involves disruption of the cell membrane, leading to interference with energy production within the bacterial cell.
Contrary to data reported for other strains, the clinically important EMRSA-16 strain MRSA252 used in this study showed an
increase in expression of the important virulence regulator RNAIII following all of the treatment conditions tested. An
adaptive response by S. aureus of reducing cell surface hydrophobicity was also observed. Two fatty acid sensitive mutants
created during this study were also shown to diplay altered pathogenesis as assessed by a murine arthritis model.
Differences in the prevalence and clinical importance of S. aureus strains might partly be explained by their responses to
antimicrobial fatty acids.
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Introduction
Staphylococcus aureus is the aetiological agent for a wide range of
human infections, including abscesses, septicaemia, arthritis and
endocarditis. The increased prevalence of meticillin resistant-
(MRSA) and vancomycin insensitive-S. aureus strains, and the
emergence of community-acquired MRSA make investigations
into the pathogenicity of this species imperative. Inevitably, this
focuses research into the development of novel antimicrobial
agents, which requires a rigorous study of staphylococcal
physiology. Long chain unsaturated free fatty acids (LC-uFFAs),
typically $C16, are known to possess anti-staphylococcal activity
and LC-uFFAs are important components of the innate immune
system. Individuals with atopic dermatitis exhibit deficient
production of the skin-specific LC-uFFA, hexadecenoic acid
[C16:1 (n-6)], which is associated with increased carriage of S.
aureus and susceptibility to bacterial skin infections [1–3]. In
human tissue and nasal fluid, the major LC-FFAs are the
unsaturated linoleic [C18:2 (n-6,9)], oleic [C18:1 (n-9)] and
palmitoleic [C16:1 (n-7)] acids and the saturated palmitic
[C16:0] and stearic [C18:0] acids [4–7]. Assay of staphylococcal
abscess homogenates has revealed the presence of anti-staphylo-
coccal activity comprising a pool of monoglycerides and free fatty
acids [8–10]. The most abundant compound present in this active
pool was identified as linoleic acid and was found at millimolar
concentrations.
FFAs of various chain lengths and with different levels of
unsaturation are primarily effective against Gram-positive bacteria
[11–18]. Inhibition of several membrane-enveloped viruses has
also been demonstrated [19–21]. Although several studies have
attempted to pinpoint the specific cellular target(s) of LC-uFFAs,
the actual anti-bacterial mechanism has not been unambiguously
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inhibit all major bacterial biosynthetic pathways within the cell,
or alternatively, that they specifically inhibit FabI, which catalyses
the final and rate-limiting step in fatty acid biosynthesis
[12,18,22,23]. Oleic acid was proposed by Won et al. [24] to
inhibit glucosyltransferases, while other proposed mechanisms for
LC-uFFA-mediated growth inhibition include peptidoglycan (PG)
precipitation, peroxidative stress, interference with energy metab-
olism and alteration of the membrane permeability or fluidity
[12,16,18,22,25,26].
A diversity of mechanisms have been proposed to account for
resistance to LC-uFFAs in S. aureus. Enhanced production of the
carotenoid staphyloxanthin (giving aureus its golden title) has been
proposed as a mechanism to relieve the inhibitory effects of
increased membrane fluidity due to insertion of LC-uFFAs into
the lipid bilayer in S. aureus [26–28]. Increased staphylococcal
resistance to LC-uFFAs was positively correlated with pigmenta-
tion, although these experiments were performed using non-
isogenic strains [28]. A fatty acid modifying enzyme (FAME),
which catalyses the esterification of FFAs with cholesterol has also
been purified from several S. aureus strains and its production
correlated with increased disease severity in an abscess model [29–
32]. Nonetheless the gene encoding FAME remains unidentified.
Furthermore, in Neisseria gonorrhoea, FFA resistance has been linked
to the presence of FFA-specific efflux pumps [33] while in S. aureus,
the expression of Fur-iron-regulated staphylococcal surface-
associated protein IsdA was identified as contributing to FA
resistance in iron-limited environments by reducing cellular
hydrophobicity [34]. Another proposed mechanism included the
increased production of a ‘protective slime’ composed of
precipitated PG complexed to fatty acids [25].
Previous studies demonstrated that S. aureus responds to the C12
monoester glycerol monolaurate (GML) and the component FFA
lauric acid by reducing levels of expression of alpha toxin (Hla)
[35–37]. Similarly, Clarke et al. [34] showed that expression of hla
was reduced following exposure of S. aureus to the LC-uFFA
hexadecenoic acid [C16:1 (n-6)]. More recently, GML was shown
to inhibit the synthesis of toxins in several Gram-positive bacteria
and also limited the effect of these toxins on eukaryotic cells [38–
40].
While the biological effects of free fatty acids as antimicrobial
compounds have been catalogued, there remains no unequivocal
identification of the targets or mechanisms of action in relation to
S. aureus. Transcriptomic and proteomic analyses have the
potential to elucidate complex cellular and metabolic responses
and are applied here for the first time to analyse the reaction of S.
aureus to the LC-uFFAs linoleic, oleic and hexadecenoic acid. In
addition, an analysis of existing well-characterised mutants and the
generation of new allelic replacement mutants based on gene array
data coupled to transposon screens was carried out to identify loci
important for survival. Finally, a murine arthritis model of
infection was used to ascertain whether two of the genes
highlighted in this study have a role in pathogenesis.
Results
Comparative resistance of S. aureus strains to
unsaturated C18 free fatty acids
The relative resistances of different strains of S. aureus to the
unsaturated C18 free fatty acids linoleic acid [C18:2 (n-6,9)] and
oleic acid [C18:1 (n-9)] were compared using a previously
described agar plate assay [13]. Many strains, such as MSSA476
and N315, were unable to grow on emulsion agar plates
containing 1 mM linoleic acid (Fig. 1A). In contrast MRSA252,
Figure 1. Inhibition of S. aureus by C18 unsaturated fatty acids. A
Graph showing percentage survival of wild-type strains of S. aureus when
these strains were incubated on BHI plates containing 0, 0.25, 0.5and 1 mM
linoleic acid. The strains analysed were SH1000 (closed box), MRSA252
(closed triangle), MSSA476 (open box) and N315 (open circle). This assay
was performed in triplicate and is representative of multiple experiments. B
Growth of a 0.5% (vol/vol) inoculum of MRSA252 in 100 ml BHI containing
0 mM fatty acid (closed triangle), 0.01 mM oleic acid (cross) or 0.01 mM
linoleicacid(openbox) at37uCwithshakingat250 rpm.RNAwasextracted
from these cells at an OD600 of 3 and analysed in microarray experiments as
t h eg r o w t he x p o s u r ec o n d i t i o n s .C Growth of a 0.5% (vol/vol) inoculum of
MRSA252 in100 ml BHIat 37uC with shaking at250 rpm with(openbox) or
without (closed triangle) the addition of 0.1 mM linoleic acid at an OD600 of
3. RNA was extracted from these cells 20 min post-exposure and analysed
in microarray experiments as the challenge conditions. The growth curves
shown in B and C were performed in biological triplicate. The error bars
shown in graphs B and C correspond to standard errors of the mean.
doi:10.1371/journal.pone.0004344.g001
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displayed high levels (.60%) of survival at millimolar concentra-
tions. Consequently, all subsequent experiments were performed
using MRSA252 and SH1000 strains of S. aureus, owing to their
enhanced growth in the presence of C18 LC-uFFAs.
Growth of MRSA252 in the presence of LC-uFFAs
To facilitate analysis of gene transcription and protein
expression, a range of different concentrations of linoleic or oleic
acid and the timing of their addition were examined during
growth (data not shown). Upon inoculation 0.01 mM linoleic acid
was determined to be the maximum concentration, which did not
retard the aerobic growth of MRSA252 in BHI broth (Fig. 1B).
Cells were subsequently grown in the presence of 0.01 mM linoleic
or oleic acid with the FFAs being added at the start of growth
(growth exposure conditions). To test the response of MRSA252 to
LC-uFFAs under slightly different conditions, a higher concen-
tration of linoleic acid (0.1 mM) was added during the late-
exponential growth phase (OD600=3) where it was observed to
reduce subsequent growth (challenge conditions) (Fig. 1C). These
culture conditions were repeated for independent samples and
cells were harvested to determine the transcriptional and
translational responses of the cells to treatment with LC-uFFAs.
The transcriptional response of S. aureus to C18 free fatty
acids
A pronounced differential transcriptional response was observed
in MRSA252 cells treated with linoleic acid when it was added to a
final concentration of 0.1 mM for 20 min during late-exponential
growth (linoleic acid challenge) compared to unexposed control
cells; 213 genes were up-regulated (Table 1) and 179 genes were
down-regulated (Table 2). When transcription was analysed for
cells grown in the presence of a lower concentration of linoleic acid
(0.01 mM) from the time of inoculation (linoleic acid growth
exposure) a correspondingly smaller subset of genes displayed
differential transcription; 37 genes were up-regulated (Table 3) and
28 genes were down-regulated (Table 4). Oleic acid differs from
linoleic acid in its degree of unsaturation, containing one less
double bond in the chain. When cells were grown under the
conditions of oleic acid growth exposure, 20 genes were up-
regulated (Table 5) and 23 genes were down-regulated (Table 6).
The sudden impositionof linoleic acid duringexponential growth
at OD600=3 (linoleic acid challenge) resulted in large-scale
transcriptional reprogramming of genes in four major discernible
categories, including:virulence, energymetabolism, stressresistance
and cell wall synthesis. In contrast, the presence of linoleic at
0.01 mM, a non-growth limitingconcentration(linoleic acid growth
exposure), resulted in changes in transcription of fewer genes in the
same categories, with the exception of cell wall synthesis.
Effect of linoleic acid on S. aureus MRSA252 transcription
A distinctive feature of linoleic acid addition to cells of
MRSA252 under both challenge and growth exposure conditions
was observed to be the 10- and 2-fold up-regulation of the
virulence regulator RNAIII, respectively (Table 1, 3). Previous
studies have not reported changes in regulation of this locus after
exposure to FFAs in S. aureus [34,35]. Moreover, after linoleic acid
challenge the virulence regulator sarA was up-regulated as was clfA,
encoding clumping factor A and genes required for capsule
formation (capF, capM, capN), while the genes encoding the
proteases staphopain and aureolysin were down-regulated
(Table 1, 2). Further virulence-associated loci up-regulated in the
presence of linoleic acid during growth included the esxA locus
encoding ESAT-6-like proteins and the genes coding for their
synthesis/secretion [41] and tcaR that encodes a MarR-like
regulator of SarS and SasF expression [42] (Table 3).
Many genes involved in sugar metabolism showed altered levels
of regulation. In particular, several genes in the fructose and
mannose metabolism pathways were down-regulated. These
include SAR0753 (fruA) and SAR0752, involved in the importation
and phosphorylation of fructose, respectively. Genes with similar
functions involving the importation and phosphorylation of
glucose, mannose, maltose and galactitol, namely SAR0235,
SAR1777 (pfkA), SAR2720, SAR2721 (pmi), SAR0242 and
SAR0263 were also down-regulated. This could indicate an
alteration of central metabolism via the action of the linoleic acid.
Here, in concert with these changes, many genes in glycolysis were
up-regulated, including SAR2684 (fda), SAR0830 (tpiA), SAR0831
(pgm) and SAR2506 (dpgm). In addition, the SAR0141 (drm),
SAR0574 and SAR0575 genes involved in pentose and glucuronate
interconversions were up-regulated, which would increase the
availability of substrates for glycolysis or pentose phosphate
pathways. The down-regulation of the putative UTP-glucose-1-
phosphate uridylyltransferases SAR2262 and SAR2579 (gtaB),
which are predicted to catalyse the conversion of glucose-1-
phosphate to UDP-glucose, would maintain the pool of phos-
phorylated glucose available for glycolysis.
In addition to increased transcription of genes encoding
glycolytic enzymes, the cells exposed to a linoleic acid challenge
alter metabolism to maintain levels of pyruvate. The up-regulation
of SAR0824 which encodes malate dehydrogenase (converting
malate to pyruvate) is predicted to increase pyruvate levels.
Concomitantly, there was down-regulation of genes involved in
pyruvate utilisation, including ldh1, SAR1088 (pycA), ald2 and
SAR0355 converting pyruvate to lactate, oxaloacetate, alanine and
cysteine, respectively. Reduced transcription of SAR2143 (ilvC)
could further lower the expenditure of cellular pyruvate via amino
acid synthesis, and down-regulation of SAR0522 and SAR0523
encoding predicted enzymes utilising glyceraldehyde-3-phosphate
would prevent diversion of this intermediate from glycolysis. The
reduced importation of substrates for glycolysis would explain
increased levels of glycolytic enzymes and modulation of other
pathways to increase pyruvate production. Under such potentially
energy starved conditions, the pool of pyruvate would be pushed
toward energy creation at the expense of less critical pathways.
There was up-regulation of many genes involved in cellular
stress responses, including the CtsR regulon genes clpB, dnaJ and
dnaK suggesting that linoleic acid addition is perceived by S. aureus
as a stressor. Moreover, the transcripts of several s
B-regulated
genes were up-regulated, including katA, asp23 and clpL, and the
crtM, crtN, crtO, crtP, crtQ genes involved in staphyloxanthin
biosynthesis. The mevalonate pathway generates the isopentenyl-
diphosphate precursor for biosynthesis of this carotenoid, and the
pathway genes mvaK1, mvaD and mvaK2 were up-regulated
accordingly (Table 1). Linoleic acid has been proposed to interfere
with membrane function by increasing fluidity, which has the
potential to perturb the electron transport chain. The production
of carotenoids, which insert into the membrane has been reported
to decrease fluidity and counteract the effect of LC-uFFAs [26]. In
response to linoleic acid challenge the menaquinone biosynthesis
pathway genes SAR1017 (menD) and SAR1018 involved in the
conversion of chorismate to menaquinone (MK), and present in an
operon with menB, were up-regulated indicating an increase in MK
biosynthesis. This up-regulated MK synthesis could be a response
to perturbation of the electron transport chain. The SAR1479,
SAR1480 (menH) and SAR1481 genes synthesise heptaprenyl
diphosphate for the isoprenoid moiety of MK-7, while SAR1278
S. aureus Response to LC-uFFAs
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Group
Functions MRSA252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change Up
Regulated P-value
Virulence Factors
and Regulators
SAR0156 capF capsular polysaccharide synthesis enzyme 2.23 4.22E-02
SAR0163 capM capsular polysaccharide synthesis enzyme 2.23 3.20E-02
SAR0164 capN capsular polysaccharide synthesis enzyme 2.83 1.79E-02
SAR0625 sarA staphylococcal accessory regulator A 2.14 1.50E-02
SAR0842 clfA clumping factor 4.12 6.58E-03
SAR2122 hld delta-hemolysin precursor 3.28 1.23E-02
SAR2295 putative exported MAP/eap domain protein 3.21 8.77E-04
SAR2443 tcaR MarR family regulatory protein 3.15 1.76E-03
RNAIII RNAIII RNAIII accessory gene regulator (agr) locus 2.01 3.02E-02
Stress Response SAR0577 proP putative proline/betaine transporter 8.31 5.78E-04
SAR0859 putative organic hydroperoxide resistance protein 3.82 1.23E-02
SAR0938 clpB putative ATPase subunit of an ATP-dependent protease 2.49 8.15E-04
SAR1344 katA catalase 5.71 1.86E-03
SAR1656 dnaJ chaperone protein 2.30 4.25E-02
SAR1657 dnaK chaperone protein 2.41 2.17E-03
SAR2273 asp23 alkaline shock protein 23 2.06 3.86E-02
SAR2276 opuD2 glycine betaine transporter 2 4.42 6.16E-03
SAR2561 alkylhydroperoxidase, AhpD family 6.83 8.77E-04
SAR2628 clpL putative ATPase subunit of an ATP-dependent protease 4.06 4.79E-03
Energy
Metabolism
SAR0113 lldP1 L-lactate permease 1 2.15 1.07E-03
SAR0188 putative isochorismatase 4.91 8.03E-04
SAR0141 drm putative phosphopentomutase 2.45 1.31E-02
SAR0574 putative hexulose-6-phosphate synthase 2.36 1.80E-03
SAR0575 putative 6-phospho-3-hexuloisomerase 2.16 5.11E-03
SAR0775 Osmoprotectant ABC transporter 2.13 4.80E-03
SAR0776 Osmoprotectant ABC transporter, permease protein 2.99 3.00E-04
SAR0824 putative malolactic enzyme 2.59 9.27E-03
SAR0830 tpiA triosephosphate isomerase 2.22 3.39E-02
SAR0831 pgm putative phosphoglycerate mutase 2.64 1.39E-02
SAR1017 menD putative menaquinone biosynthesis bifunctional protein 2.24 1.65E-03
SAR1018 putative hydrolase 2.80 1.65E-03
SAR2386 putative NAD-dependent dehydrogenase 3.73 3.00E-04
SAR2506 dpgm putative phosphoglycerate mutase 2.06 7.33E-04
SAR2684 fda fructose-bisphosphate aldolase class I 2.02 5.85E-03
SAR2687 putative AMP-binding enzyme 2.01 9.65E-03
SAR2724 isochorismatase family protein 3.00 8.30E-04
DNA Repair and
Replication
SAR0363 ssb putative single-strand DNA-binding protein 2.26 3.29E-03
SAR0744 putative DNA photolyase 3.46 6.97E-04
SAR0813 uvrA excinuclease ABC subunit A 2.45 2.06E-03
SAR0836 rnr putative ribonuclease R 3.40 3.55E-03
SAR0837 smpB putative tmRNA-binding protein 3.07 3.70E-04
Protein Synthesis SAR0364 rpsR 30S ribosomal protein S18 2.40 1.99E-02
SAR0552 fus translation elongation factor G 2.10 3.39E-02
SAR1638 rpoD RNA polymerase sigma factor 2.86 3.70E-04
SAR2308 rplQ 50S ribosomal protein L17 2.60 1.99E-02
SAR2309 rpoA DNA-directed RNA polymerase alpha chain 2.36 3.35E-02
S. aureus Response to LC-uFFAs
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Functions MRSA252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change Up
Regulated P-value
SAR2310 rpsK 30S ribosomal protein S11 2.46 3.77E-02
SAR2311 rpsM 30S ribosomal protein S13 2.45 3.12E-02
SAR2313 infA translation initiation factor IF-1 2.08 1.49E-02
SAR2728 preprotein translocase SecA subunit-like protein 3.85 6.58E-03
Peptidoglycan
Synthesis
SAR0878 csdB putative selenocysteine lyase 2.52 3.07E-02
SAR1026 atl bifunctional autolysin precursor 2.65 6.16E-03
SAR1158 mraY phospho-N-acetylmuramoyl-pentapeptide-transferase 2.13 9.56E-04
SAR1159 murD UDP-N-acetylmuramoylalanine–D-glutamate ligase 2.39 7.64E-03
SAR1160 putative cell division protein 2.10 1.31E-02
SAR1290 putative exported CHAP domain protein 3.17 6.97E-04
SAR1430 murG putative N-acetylglucosamine transferase 5.26 1.86E-03
SAR1761 lysP lysine-specific permease 2.07 3.01E-02
SAR2109 dapE putative succinyl-diaminopimelate desuccinylase 4.89 3.00E-03
SAR2188 murA1 putative carboxyvinyltransferase 2.94 6.54E-03
SAR2269 putative alanine racemase 2.64 1.78E-03
SAR2346 fmhB putative pentaglycine interpeptide biosynthesis protein 2.49 4.22E-03
SAR2394 putative protein associated with cell-envelope regulation 2.34 2.55E-03
SAR2420 hutG arginase family protein 2.83 4.71E-03
SAR2521 putative membrane GtrA-like protein 3.11 5.78E-04
Fatty Acid
Metabolism
SAR1438 conserved hypothetical protein 2.64 4.94E-03
SAR2187 fabZ putative hydroxymyristoyl-(acyl carrier protein) dehydratase 2.41 4.22E-02
Carotenoid
Biosynthesis
SAR0596 mvaK1 mevalonate kinase 2.32 3.00E-04
SAR0597 mvaD mevalonate diphosphate decarboxylase 3.35 9.23E-04
SAR0598 mvaK2 phosphomevalonate kinase 3.18 5.09E-04
SAR2642 crtN squalene synthase 4.95 8.03E-04
SAR2643 crtM squalene desaturase 7.18 2.38E-02
SAR2645 crtQ putative glycosyl transferase 6.07 3.00E-03
SAR2646 crtP putative phytoene dehydrogenase related protein 6.28 1.73E-03
SAR2647 putative membrane protein 4.47 1.73E-03
Antibiotic
Resistance
SAR0139 putative tetracycline resistance protein 4.06 1.59E-03
SAR1622 metallo-beta-lactamase superfamily protein 2.08 3.93E-03
SAR1785 metallo-beta-lactamase superfamily protein 3.05 1.08E-03
SAR1831 blaZ beta-lactamase precursor 2.02 2.72E-02
SAR2505 mdeA putative transport system protein 3.93 7.74E-03
SAR2558 conserved hypothetical beta-lactamase-like protein 8.72 3.70E-04
SAR2632 Putative MMPL efflux pump 2.03 4.58E-02
SAR2655 putative glyoxalase 5.15 1.11E-03
SAR2668 hypothetical aminoglycoside phosphotransferase protein 4.35 6.30E-03
Miscellaneous SAR1738 tnpB2 transposase B 2 2.14 1.25E-03
SAR2725 sasF putative surface anchored protein 16.80 4.68E-05
Metabolism SAR0108 putative peptidase 2.98 5.22E-03
SAR0109 putative transporter protein 2.37 1.52E-02
SAR0170 putative cation efflux system protein 2.50 1.77E-03
SAR0306 ABC transporter ATP-binding protein 6.10 1.68E-03
SAR0324 putative lipoate-protein ligase A 2.09 4.31E-03
SAR0325 putative reductase 4.80 8.17E-04
SAR0556 ThiJ/PfpI family protein 7.20 7.59E-04
Table 1. Cont.
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SAR0589 putative amino acid permease 4.19 3.75E-03
SAR0600 pyridine nucleotide-disulphide oxidoreductase protein 2.26 2.77E-04
SAR0624 putative esterase 6.49 7.59E-04
SAR0729 putative acetyltransferase 2.92 3.23E-03
SAR0732 putative acetyltransferase 2.34 3.00E-04
SAR0756 aldo/keto reductase family protein 2.96 6.16E-04
SAR0757 putative glucosyl transferase 3.49 7.59E-04
SAR0764 putative 6-pyruvoyl tetrahydropterin synthase 3.70 8.03E-04
SAR0841 putative acetyltransferase 5.22 3.29E-03
SAR0883 putative dioxygenase 5.40 1.75E-03
SAR0903 putative pyridine nucleotide-disulphide oxidoreductase 2.82 3.00E-04
SAR0953 transport system extracellular binding lipoprotein 2.18 6.05E-03
SAR1076 Spermidine/putrescine-binding protein homolog. 4.46 8.77E-04
SAR1247 putative tRNA pseudouridine synthase B 2.31 2.10E-03
SAR1340 thrB homoserine kinase 2.20 3.71E-02
SAR1431 putative acetyltransferase 4.58 1.80E-03
SAR1439 dfrB dihydrofolate reductase type I 2.13 6.34E-03
SAR1440 thyA thymidylate synthase 5.32 1.58E-03
SAR1585 malR maltose operon transcriptional repressor 2.21 2.20E-02
SAR1655 putative methyltransferase 2.25 6.08E-03
SAR2210 aldehyde dehydrogenase family protein 5.48 1.51E-03
SAR2352 moaA putative molybdenum cofactor biosynthesis protein A 2.07 1.86E-03
SAR2385 putative Na+/H+ antiporter 2.35 1.34E-02
SAR2395 inositol monophosphatase family protein 2.90 7.59E-04
SAR2413 putative short chain dehydrogenase 4.63 3.66E-03
SAR2460 putative acetyltransferase (GNAT) family protein 2.26 6.97E-04
SAR2485 narH nitrate reductase beta chain 2.16 1.02E-02
SAR2541 putative carboxylesterase 2.45 1.79E-02
SAR2544 ABC transporter ATP-binding protein 6.01 1.68E-03
SAR2559 putative short chain dehydrogenase 6.85 6.16E-04
SAR2659 putative short chain dehydrogenase 2.65 1.76E-03
SAR2661 putative hydrolase 8.11 8.27E-04
SAR2754 hisIE putative histidine biosynthesis bifunctional protein 2.09 2.19E-02
SAR2778 putative nickel transport protein 2.51 3.59E-03
Hypothetical
Genes
SAR0111 putative myosin-crossreactive antigen 5.96 2.43E-03
SAR0112 putative membrane protein 3.57 4.80E-04
SAR0171 hypothetical protein 2.64 3.01E-02
SAR0269 LacI family regulatory protein 2.57 3.59E-03
SAR0299 hypothetical protein 2.05 4.99E-02
SAR0305 putative membrane protein 3.89 6.02E-03
SAR0390 putative lipoprotein 3.97 1.68E-03
SAR0392 putative membrane protein 2.54 1.20E-02
SAR0405 hypothetical protein 2.76 1.07E-02
SAR0444 putative lipoprotein 2.31 2.16E-03
SAR0498 yabJ putative regulatory protein 3.65 1.07E-03
SAR0499 spoVG stage V sporulation protein G 2.83 1.11E-02
SAR0601 putative DNA-binding protein 2.15 4.48E-04
SAR0670 putative sensor histidine kinase protein 2.01 4.80E-04
SAR0721 multicopper oxidase protein 2.29 4.39E-03
Table 1. Cont.
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SAR0733 conserved hypothetical protein 3.04 1.99E-03
SAR0734 conserved hypothetical protein 2.23 1.59E-03
SAR0821 conserved hypothetical protein 3.19 6.54E-03
SAR0825 conserved hypothetical protein 5.06 1.86E-03
SAR0840 putative membrane protein 5.25 2.63E-03
SAR0849 hypothetical protein 2.81 6.05E-03
SAR0850 hypothetical protein 2.94 6.81E-04
SAR0854 hypothetical protein 4.07 1.56E-02
SAR0855 hypothetical protein 2.53 1.94E-03
SAR0867 hypothetical protein 2.54 4.55E-03
SAR0877 conserved hypothetical protein 2.34 3.01E-02
SAR0879 NifU-like protein 2.06 3.39E-02
SAR0880 conserved hypothetical protein 2.14 3.47E-03
SAR0882 putative membrane protein 4.05 4.12E-03
SAR0931 putative membrane protein 7.87 4.28E-04
SAR1055 hypothetical protein 4.50 3.08E-03
SAR1077 putative membrane protein 2.54 5.69E-03
SAR1227 conserved hypothetical protein 2.11 1.71E-02
SAR1258 putative DNA-binding protein 2.12 3.07E-04
SAR1289 putative exported protein 3.49 1.65E-03
SAR1306 hypothetical protein 2.20 5.66E-03
SAR1429 putative membrane protein 5.74 1.84E-03
SAR1528 hypothetical phage protein 6.04 4.99E-02
SAR1623 conserved hypothetical protein 2.29 1.39E-02
SAR1669 conserved hypothetical protein 2.01 1.03E-02
SAR1670 conserved hypothetical protein 2.53 5.36E-03
SAR1671 probable nicotinate-nucleotide adenylyltransferase 2.03 8.07E-03
SAR1816 putative membrane protein 2.82 6.16E-04
SAR1854 hypothetical protein 4.98 1.27E-03
SAR1965 ThiJ/PfpI family protein 2.25 4.83E-02
SAR1970 conserved hypothetical protein 2.17 4.68E-02
SAR1972 putative exported protein 5.71 6.59E-03
SAR2010 hypothetical protein 3.49 6.58E-03
SAR2047 hypothetical phage protein 2.12 1.16E-02
SAR2085 hypothetical phage RecT family protein 2.18 9.84E-04
SAR2088 hypothetical phage protein 2.62 2.28E-02
SAR2094 hypothetical phage protein 2.69 3.06E-03
SAR2095 hypothetical phage protein 4.03 5.44E-03
SAR2098 hypothetical phage protein 2.02 2.87E-03
SAR2189 putative membrane protein 2.94 6.07E-03
SAR2232 conserved hypothetical protein 8.26 2.06E-03
SAR2245 putative transcriptional antiterminator 6.03 1.76E-03
SAR2270 hypothetical IucA/IucC family protein 3.36 3.80E-03
SAR2274 putative membrane protein 4.59 2.04E-03
SAR2275 putative membrane protein 3.98 6.16E-04
SAR2347 putative membrane protein 2.21 6.54E-03
SAR2392 conserved hypothetical protein 3.03 5.20E-03
SAR2393 putative molydopterin dinucleotide binding domain protein 3.26 2.50E-03
SAR2444 putative membrane protein 4.38 2.77E-04
SAR2469 putative pyridoxamine 59-phosphate oxidase 4.72 1.11E-03
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genes were down-regulated, which is consistent with a reduction of
the MK-7 isoprenolog. S. aureus synthesises various MK isopreno-
logs, up to MK-9, and alters their ratio in response to changes in
temperature and oxygen levels [43].
Genes concerned with cell wall biosynthesis were observed to be
modulated in linoleic acid challenge conditions but not in the growth
exposure conditions. The genes mraY, murD, murG and murA1 involved
in the synthesis of the pentaglycine precursor in PG synthesis were up-
regulated, as was atl, encoding the major cellular autolysin (Table 1)
[44]. There was down-regulation of the two-component regulatory
system lytRS, the holin-like lrgA and cidA and the putative
transglycosylase SAR1807, which have cell wall modulatory roles
(Table 2) [45,46]. In addition to these changes, an assortment of
transcriptionally modulated genes was observed, which would
function to maintain the level of constituents for the PG-pentapeptide
precursor. SAR2109 (dapE), which catalyses the formation of a
substrate for lysine biosynthesis and the lysine-specific permease
SAR1761 (lysP) were up-regulated, and this would increase the pool of
L-lysine in the cell. Up-regulation of SAR2420 (hutG), and down-
regulation of SAR2669 encoding a putative dihydroorotate dehydro-
genase, SAR0228 encoding a putative glutamine amidotransferase and
SAR1752 (hemA), in concert, would maintain glutamate levels within
the cell. SAR2269, a putative alanine racemase, was up-regulated
thereby increasing synthesis of D-alanine by isomerising L-alanine.
The microarray data also revealed increased transcription of the tagA,
tagG and tagB genes concerned with teichoic acid biosynthesis.
The fatty acid biosynthesis enzyme FabI was previously
reported to be inhibited by linoleic acid and was therefore
proposed to be a key target for its antibacterial activity [23]. Here,
within fatty acid metabolism, only fabZ was up-regulated in linoleic
acid challenge conditions, whereas fadD, fadX and plc were down-
regulated. fabZ is directly downstream of murA1 within a predicted
operon which may explain why fabZ alone is up-regulated amongst
the fatty acid biosynthesis genes.
Quantitative Real-Time PCR
Confirmation of the microarray data was performed using qRT-
PCR to test selected transcriptional changes of known genes from
different functional subsets. To this end, the expression level of
genes involved in staphyloxanthin synthesis (crtM), PG biosynthesis
(murG, cidA and lytR), stress responses (katA and clpB), virulence
(RNAIII, sarA, arcA, hla and spa) and fatty acid metabolism (fabZ,
fabI, fadD and fadA) were analysed. In addition, the sasF gene was
analysed to confirm the particularly high levels of transcript that
were observed under the challenge experimental conditions. Most
genes tested showed the same pattern of up- or down-regulation
(Table 7) that was identified by microarray analysis under any
given set of conditions. The only exceptions were the fatty acid
degradation pathway genes fadD and fadA. While fadD was 2.15
fold down-regulated after linoleic acid challenge when analysed by
microarray, this was identified as a 3.16 fold up-regulation when
tested by qRT-PCR. The fadA gene lies within a predicted operon
with fadD and would thus be co-regulated. A 3.1 fold up-
regulation of fadA was similarly measured by qRT-PCR when the
cells were challenged with linoleic acid, which supports the
reproducibility of the qRT-PCR analysis of fadD and its likely
operon arrangement with fadA. Therefore, with the exception of
the fad operon, the microarray data was shown to be consistent
when tested by qRT-PCR.
The transcription ofa subsetofgeneswasexaminedbyqRT-PCR
during mid-exponential growth phase and late exponential-phase
(OD600=8)(Table7),toexaminethepotentialeffectoftheincreased
Group
Functions MRSA252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change Up
Regulated P-value
SAR2496 putative solute binding lipoprotein 2.60 3.66E-03
SAR2525 hypothetical protein 5.28 2.33E-05
SAR2532 CapD domain protein 2.48 4.16E-03
SAR2542 putative transport protein 2.01 5.64E-03
SAR2543 putative membrane protein 6.37 6.16E-04
SAR2568 hypothetical protein 4.66 1.65E-03
SAR2656 conserved hypothetical protein 3.35 6.16E-04
SAR2657 hypothetical protein 2.40 8.80E-04
SAR2658 TetR family regulatory protein 2.22 4.39E-04
SAR2660 conserved hypothetical protein 7.26 6.16E-04
SAR2665 conserved hypothetical protein 2.19 4.06E-03
SAR2666 hypothetical protein 2.75 1.87E-03
SAR2667 hypothetical protein 2.19 1.37E-02
SAR2688 hypothetical protein 7.55 3.70E-04
SAR2689 hypothetical protein 2.53 1.84E-02
SAR2726 conserved hypothetical protein 5.07 1.80E-03
SAR2727 glycosyl transferase, group 1 family protein 4.11 6.70E-03
SAR2739 conserved hypothetical protein 4.21 2.06E-03
SAR2740 conserved hypothetical protein 2.05 3.09E-02
SAR2777 putative DNA-binding protein 2.40 1.90E-03
SAR2780 putative membrane protein 7.38 4.80E-04
doi:10.1371/journal.pone.0004344.t001
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Group
Functions MRSA 252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change
Down Regulated P-value
Virulence Factors
and Regulators
SAR0105 plc 1-phosphatidylinositol phosphodiesterase 3.85 4.39E-04
SAR1574 fur iron uptake regulatory protein 2.08 2.46E-02
SAR1984 ferritin 2.56 4.39E-03
SAR2001 staphopain protease 2.44 3.00E-04
SAR2474 sarZ MarR family virulence regulator 2.22 2.18E-02
SAR2155 rsbU putative sigma factor sigB regulation protein 2.56 1.58E-03
SAR2715 argR arginine repressor family protein 2.27 4.27E-03
SAR2716 aur zinc metalloproteinase aureolysin precursor 2.17 1.76E-03
Energy
Metabolism
SAR0234 ldh1 L-lactate dehydrogenase 1 2.94 2.99E-05
SAR0235 putative PTS system, IIBC component 2.22 1.30E-03
SAR0242 putative galactitol PTS component 2.13 1.76E-02
SAR0263 putative PTS system protein 2.50 3.44E-02
SAR0355 Cys/Met metabolism PLP-dependent enzyme 2.04 2.74E-02
SAR0522 putative pyridoxal 5-phosphate biosynthesis protein 3.03 3.00E-04
SAR0523 SNO glutamine amidotransferase family protein 2.70 3.70E-04
SAR0752 putative phosphofructokinase 2.38 3.27E-02
SAR0753 fruA fructose-specific PTS system component 2.50 3.78E-02
SAR0766 glutamine amidotransferase class-I protein 2.04 6.16E-04
SAR1088 putative pyruvate carboxylase 2.5 8.78E-04
SAR1450 tdcB putative threonine dehydratase 2.22 5.47E-03
SAR1451 ald2 alanine dehydrogenase 2 3.03 1.15E-03
SAR1777 pfkA 6-phosphofructokinase 2.86 2.87E-03
SAR1789 ackA acetate kinase 2.33 9.23E-03
SAR2143 ilvC ketol-acid reductoisomerase 2.22 2.80E-02
SAR2213 fba putative tagatose-bisphosphate aldolase 3.13 6.59E-03
SAR2262 putative uridylyltransferase 2.27 8.35E-03
SAR2579 gtaB putative uridylyltransferase 2.63 6.84E-03
SAR2720 putative PTS system component 4.17 3.54E-03
SAR2721 pmi mannose-6-phosphate isomerase 3.57 2.76E-03
Cell Wall
Synthesis
SAR0228 putative glutamine amidotransferase class-I 2.13 2.08E-03
SAR0257 lytS autolysin sensor kinase protein 3.33 3.00E-03
SAR0258 lytR autolysin response regulator protein 3.57 9.15E-03
SAR0259 lrgA holin-like protein 2.22 1.20E-03
SAR0646 tagA teichoic acid biosynthesis protein 2.78 6.80E-03
SAR0648 tagG teichoic acid ABC transporter permease protein 2.38 1.32E-02
SAR0649 tagB teichoic acid biosynthesis protein 2.50 4.41E-04
SAR1143 putative carbamate kinase 2.27 6.79E-03
SAR1752 hemA glutamyl-tRNA reductase 2.27 3.93E-02
SAR1807 putative transglycosylase 2.04 8.78E-04
SAR2472 gltT putative proton/sodium-glutamate symport protein 2.04 2.97E-02
SAR2621 cidA holin-like protein 2.27 1.18E-02
SAR2669 putative dihydroorotate dehydrogenase 2.86 3.75E-03
Fatty Acid
Metabolism
SAR0225 fadD putative acyl-CoA dehydrogenase 2.17 3.27E-02
SAR0227 fadX putative acetyl-CoA transferase 2.13 4.95E-02
SAR0803 conserved hypothetical protein 3.23 1.02E-02
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Carotenoid
Biosynthesis
SAR1278 miaA putative isopentenylpyrophosphate transferase 2.00 9.23E-03
SAR1479 putative heptaprenyl diphosphate synthase 2.78 1.62E-02
SAR1480 menH heptaprenylnaphthoquinone methyltransferase 2.27 3.54E-02
SAR1481 putative hexaprenyl diphosphate synthase 3.13 1.79E-02
DNA Repair and
Replication
SAR0001 dnaA chromosomal replication initiator protein DnaA 2.04 2.17E-03
SAR0004 recF DNA replication and repair protein RecF 2.08 8.51E-03
SAR0028 repB replication protein (pseudogene) 4.35 1.48E-02
SAR0485 holB putative DNA polymerase III, delta’ subunit 3.03 1.26E-02
SAR0711 putative replication initiation protein 2.50 3.43E-02
SAR2429 putative 3-methylpurine glycosylase 2.22 1.87E-03
Metabolism SAR0246 ispD conserved hypothetical protein 2.00 2.27E-03
SAR0261 putative nitric oxide reductase 2.22 6.16E-04
SAR0302 putative formate/nitrite transporter 2.38 8.03E-03
SAR0524 nupC nucleoside permease 2.94 3.96E-03
SAR0562 putative deoxyadenosine kinase protein 2.17 2.64E-02
SAR0563 putative deaminase 2.50 3.75E-03
SAR0569 putative glycosyl transferase 2.13 4.40E-03
SAR0642 ABC transporter permease protein 2.56 9.65E-03
SAR0643 ABC transporter ATP-binding protein 3.70 9.25E-03
SAR0655 putative Na+ dependent nucleoside transporter 2.17 2.25E-03
SAR0743 putative sodium:sulfate symporter protein 2.22 4.39E-04
SAR0847 nuc thermonuclease precursor 3.33 3.70E-04
SAR0916 putative peptidyl-prolyl cis-trans isomerase 2.13 6.54E-03
SAR1008 putative glycosyl transferases 4.00 1.65E-03
SAR1014 acetyltransferase (GNAT) family protein 2.27 6.54E-03
SAR1090 ctaB putative protoheme IX farnesyltransferase 2.04 2.66E-02
SAR1185 putative guanylate kinase 2.78 6.16E-03
SAR1449 amino acid permease 2.50 2.65E-03
SAR1478 ndk putative nucleoside diphosphate kinase 2.38 3.03E-02
SAR1598 arginine repressor 2.50 3.23E-03
SAR1627 5-formyltetrahydrofolate cyclo-ligase family protein 2.78 2.27E-03
SAR1707 putative ATPase 2.13 1.36E-02
SAR1714 relA GTP pyrophosphokinase 2.27 3.96E-03
SAR1717 secF putative protein-export membrane protein 2.27 6.05E-03
SAR1804 putative acyltransferase 2.44 2.99E-02
SAR2129 scrR sucrose operon repressor 2.56 1.38E-02
SAR2130 ammonium transporter family protein 2.04 1.65E-03
SAR2340 acetyltransferase (GNAT) family protein 3.03 8.77E-04
SAR2363 modA putative molybdate-binding lipoprotein precursor 2.08 2.97E-02
SAR2432 CorA-like Mg2+ transporter protein 2.44 5.61E-03
SAR2493 putative formate/nitrite transporter 2.22 8.71E-03
SAR2594 ABC transporter ATP-binding protein 2.38 1.65E-03
SAR2789 putative subtilase family protease 2.04 2.27E-03
Hypothetical
Genes
SAR0013 putative membrane protein 2.17 1.81E-02
SAR0024 conserved hypothetical protein 3.03 2.27E-03
SAR0030 hypothetical protein 2.38 6.16E-03
SAR0048 putative membrane protein 2.08 1.08E-02
SAR0061 putative membrane protein 2.08 4.25E-02
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SAR0063 hypothetical protein 2.56 1.02E-02
SAR0075 hypothetical protein 2.04 6.16E-04
SAR0078 hypothetical protein 2.08 9.65E-03
SAR0097 putative DNA-binding protein 2.17 2.99E-03
SAR0145 putative lipoprotein 2.13 1.56E-02
SAR0197 hypothetical protein 286 2.14E-02
SAR0216 putative lipoprotein 2.04 6.16E-04
SAR0338 putative membrane protein 2.86 2.40E-03
SAR0383 abortive infection bacteriophage resistance related 4.76 1.99E-02
SAR0618 putative iron compound-binding protein 2.27 4.08E-02
SAR0673 conserved hypothetical protein 2.70 4.55E-03
SAR0694 putative bacteriocin 2.38 3.75E-03
SAR0695 putative bacteriocin-immunity membrane protein 2.22 2.08E-03
SAR0718 putative membrane protein 3.33 9.93E-04
SAR0761 putative lipoprotein 2.86 3.00E-04
SAR0793 hypothetical protein 2.56 1.58E-02
SAR0846 secreted von Willebrand factor-binding homolog 2.17 1.94E-02
SAR0890 conserved hypothetical protein 2.56 8.06E-04
SAR0893 putative membrane protein 2.13 4.74E-02
SAR0898 conserved hypothetical protein 2.70 1.59E-02
SAR0899 conserved hypothetical protein 2.33 4.94E-03
SAR0915 kinase-associated protein B 2.44 8.06E-04
SAR0970 protozoan/cyanobacterial globin family protein 2.38 1.11E-02
SAR0971 conserved hypothetical protein 2.78 1.87E-03
SAR0979 putative membrane protein 2.50 2.25E-03
SAR0981 putative esterase 2.44 1.55E-03
SAR0982 putative restriction-modification system protein 2.44 1.37E-03
SAR0983 putative restriction-modification system protein 2.56 2.42E-03
SAR0985 putative 29,59 RNA ligase family 2.13 2.32E-02
SAR0987 putative monogalactosyldiacylglycerol synthase 2.56 6.54E-03
SAR1066 putative lipoprotein 2.50 4.74E-02
SAR1085 conserved hypothetical protein 2.33 3.44E-02
SAR1086 conserved hypothetical protein 3.45 6.54E-03
SAR1095 conserved hypothetical protein 2.86 2.16E-02
SAR1114 putative cell division protein ZapA 2.38 3.96E-03
SAR1148 putative DNA-binding protein 2.38 2.66E-02
SAR1154 MraZ protein 2.50 3.00E-03
SAR1312 hypothetical protein 3.85 3.27E-02
SAR1315 hypothetical protein 2.38 2.99E-03
SAR1316 hypothetical protein 2.27 1.79E-02
SAR1320 hypothetical protein 4.00 1.46E-02
SAR1335 putative exported protein 2.27 7.38E-03
SAR1389 conserved hypothetical protein (pseudogene) 2.33 5.63E-03
SAR1448 major facilitator superfamily transporter protein 2.04 4.57E-03
SAR1556 putative phage regulatory protein 2.08 5.64E-03
SAR1558 putative phage lipoprotein 2.44 1.24E-03
SAR1559 hypothetical phage protein 2.33 4.80E-04
SAR1560 hypothetical phage protein 2.04 1.72E-02
SAR1561 putative phage membrane protein 2.13 1.10E-03
SAR1581 conserved hypothetical protein 2.86 1.81E-02
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regulated genes (e.g. spa, hla and sarA). qRT-PCR analysis was
performed on MRSA252 genes under linoleic and oleic acid growth
exposure conditions. The RNAIII and clpB transcripts were
consistently up- or down-regulated, respectively, at all of the points
tested during growth; at OD600=8 RNAIII was massively up-
regulated (.150-fold) in the presence of either linoleic or oleic acid.
The transcription of sarA was up-regulated 1.5- to 2-fold in post-
exponential phaseintheseconditions. Post-exponential transcription
of hla was .6-fold higher after growth with either linoleic or oleic
acid in comparison with the untreated control. Interestingly, this
increase was moderate compared to that observed for RNAIII of the
agr locus, which is known to up-regulate expression of hla.T h i s
reflects the complex regulation of hla and may be due to the increase
in sarA levels.
Several genes showed fluctuations in relative transcript levels
during the growth cycle. For example, arcA transcription varied
over the different sample points, with gene up-regulation at
OD600=3.0 for the linoleic growth experiment as per the
microarray results. However, arcA was down-regulated in post-
exponential phasef growth phase in the presence of linoleic acid.
The observation of increased expression of RNAIII, hla and spa
in MRSA252 in response to LC-uFFAs is significantly different to
previously published experiments for these transcripts in alterna-
tive strains [34,35]. The expression of a large subset of genes,
confirmed by qRT-PCR to be altered following exposure of
MRSA252 to linoleic acid (Table 7), were subsequently examined
in SH1000 to determine whether they were similarly regulated
(Table 8). This revealed that in SH1000 the up- or down-
regulation of several genes was in direct contrast to the pattern
Table 2. Cont.
Group
Functions MRSA 252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change
Down Regulated P-value
SAR1592 conserved hypothetical protein 2.27 1.16E-02
SAR1699 conserved hypothetical protein 2.00 3.92E-03
SAR1706 putative transcriptional regulator 3.45 2.16E-02
SAR1708 conserved hypothetical protein 2.04 3.14E-03
SAR1770 putative membrane protein 2.13 2.99E-03
SAR1834 putative leucyl-tRNA synthetase 2.17 3.65E-02
SAR1885 hypothetical protein 2.63 6.97E-04
SAR1897 hypothetical protein 3.03 2.86E-02
SAR1935 probable phosphoesterase 2.78 2.37E-03
SAR1938 putative DNA-binding protein 2.38 2.80E-02
SAR2020 putative membrane protein 2.44 6.39E-03
SAR2035 putative exported protein 2.86 1.61E-02
SAR2113 hypothetical protein 2.86 4.64E-02
SAR2114 hypothetical protein 2.56 3.43E-02
SAR2115 hypothetical protein 2.86 4.22E-02
SAR2118 putative membrane protein 2.00 3.28E-03
SAR2119 membrane anchored protein 2.44 1.08E-03
SAR2156 pemK-like protein 3.03 5.61E-03
SAR2219 hypothetical protein 2.78 6.21E-03
SAR2261 putative membrane protein 2.08 6.02E-04
SAR2263 putative membrane protein 2.17 2.89E-03
SAR2299 hypothetical protein 2.04 3.47E-03
SAR2369 putative acyl-CoA dehydrogenase 2.86 1.94E-03
SAR2425 putative membrane protein 2.13 5.63E-03
SAR2428 putative membrane protein 2.00 3.23E-03
SAR2435 putative acyl hydrolase 2.50 3.02E-02
SAR2439 tetR family regulatory protein 2.22 3.23E-03
SAR2473 putative exported protein 3.85 3.97E-03
SAR2500 putative lipoprotein 2.86 8.48E-04
SAR2546 putative lipoprotein 3.13 2.76E-02
SAR2595 putative membrane protein 2.78 1.65E-03
SAR2718 putative exported protein 2.04 4.80E-04
SAR2719 transcriptional regulator 3.13 3.07E-04
SAR2792 putative membrane protein 3.85 2.78E-03
SAR2793 putative membrane protein 3.70 8.17E-04
doi:10.1371/journal.pone.0004344.t002
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and qRT-PCR data showed that there was a large up-regulation of
RNAIII after challenge or growth exposure in MRSA252,
pronounced down-regulation was observed in SH1000 by qRT-
PCR. Contrasts in regulation between MRSA252 and SH1000
were also observed for sarA, spa and sasF. However, several genes
not predicted to be RNAIII-regulated, including lytR, clpB, fabI,
murG, and arcA exhibited similar patterns of regulation in both
strains under the conditions tested.
Proteomic analysis
The proteome of MRSA252 was analysed by 2D-PAGE to
identify protein expression changes in exponentially growing cells
that were exposed to linoleic acid under the challenge conditions
used for the microarray experiments. This analysis was performed
to determine whether the large-scale transcriptional modulation
described above was translated into a correspondingly large-scale
proteomic shift. Under these conditions, 58 proteins were
significantly (P#0.05) up-regulated $2-fold and 15 proteins were
Table 3. MRSA252 genes up-regulated during growth in the presence of linoleic acid (0.01mM) (linoleic acid growth exposure).
Group
Functions
MRSA252
ORF
MRSA252
Gene MRSA252 Gene Product
Fold Change
Up Regulated P-value
Virulence
Factors and
Regulators
SAR0279 esxA virulence factor esxA 5.93 7.03E-08
SAR0280 esaA putative membrane protein 4.32 4.53E-06
SAR0281 essA putative membrane protein 2.70 1.66E-03
SAR0282 esaB conserved hypothetical protein 2.65 3.35E-03
SAR0284 essC putative membrane protein 2.56 1.25E-03
SAR0284v essC putative membrane protein 2.49 4.23E-03
SAR2123 agrB putative autoinducer processing protein 9.36 1.74E-05
SAR2125 agrC autoinducer sensor protein 5.39 4.33E-05
SAR2126 agrA autoinducer sensor protein response regulator protein 2.25 1.41E-03
agrIII agrIII Class III accessory gene regulator (agr) locus 8.71 4.16E-06
RNAIII RNAIII RNAIII accessory gene regulator (agr) locus 10.20 1.21E-05
Metabolism SAR0150 adhE putative aldehyde-alcohol dehydrogenase 2.25 1.67E-02
SAR0190 glcA glucose-specific PTS transporter protein, IIABC component 2.05 3.76E-02
SAR0829 pgk phosphoglycerate kinase 2.76 2.16E-03
SAR0830 tpiA triosephosphate isomerase 2.75 1.69E-03
SAR0831 pgm putative phosphoglycerate mutase 2.83 2.22E-03
SAR0832 eno putative enolase 2.15 5.88E-03
SAR2296 alsD putative acetolactate decarboxylase 2.43 3.32E-03
SAR2297 alsS putative acetolactate synthase 2.17 1.41E-03
SAR2618 glcB PTS system, glucose-specific IIABC component 2.78 1.41E-02
SAR2711 arcC carbamate kinase 2.40 3.41E-02
SAR2712 arcD arginine/ornithine antiporter 2.21 1.88E-02
SAR2713 arcB putative ornithine carbamoyltransferase 2.31 1.88E-02
SAR2714 arcA arginine deiminase 2.89 1.41E-02
Hypothetical
Genes
SAR0111 putative myosin-crossreactive antigen 2.44 6.52E-05
SAR0277 putative exported protein 3.76 4.22E-05
SAR0278 putative CHAP domain protein 2.89 1.22E-04
SAR0299 possible pseudogene 2.95 3.30E-03
SAR0301 putative membrane protein 3.44 1.93E-03
SAR0385 similar to putative pathogenicity island gene orf3 4.09 1.93E-03
SAR0839 putative lipoprotein 3.36 5.41E-05
SAR1564 hypothetical protein 2.09 5.32E-04
SAR1565 putative lipoprotein 2.38 3.02E-03
SAR2426 putative membrane protein 2.09 2.11E-03
SAR2427 ABC transporter ATP-binding protein 2.14 4.82E-03
SAR2428 putative membrane protein 3.73 1.21E-05
SAR2569 hypothetical protein 6.01 4.75E-02
doi:10.1371/journal.pone.0004344.t003
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used to identify the most intense protein spots on the gel
corresponding to proteins that were modulated by linoleic acid,
and the identities of 38 up-regulated and 5 down-regulated
proteins were unambiguously determined (Table 9 and 10). There
was strong agreement between the observed changes in protein
expression due to linoleic acid challenge exposure and the encoded
functions of the genes modulated in the microarray experiments.
In terms of the assigned metabolic pathways, the interpreted
effects of the fatty acid upon the cell were therefore corroborated.
Proteins associated with stress responses and PG and MK
biosynthesis were modulated in response to linoleic acid. Similarly,
the CapA protein involved in capsule biosynthesis was up-
regulated over 3-fold. From the proteomic data, challenge with
linoleic acid resulted in up-regulation of glycolysis pathway
proteins and those linked to pyruvate metabolism. Moreover, the
proteomic data were often complementary to those from the
microarrays. Several proteins within the glycolysis and pyruvate
metabolism pathways were up-regulated (e.g Gap1, Pgi), whereas
all glycolytic genes except eno were up-regulated in the microarray
experiment. A few contradictions were observed between the
microarray and proteomics data. The ald2, ackA, ispD, SAR0985
and SAR2369 proteins were determined by proteomics to be up-
regulated but were down-regulated according to microarray
analysis.
In addition to linoleic acid, the effect of the skin-associated LC-
uFFA hexadecenoic acid [C16:1 (n-6)] on the cellular proteome was
studied to determine whether there was a common response to LC-
uFFAs on S. aureus MRSA252. Analysis of 2D-SDS-PAGE gels
revealed strong spot conservation for proteins exhibiting modulated
expression in response to hexadecenoic acid compared to linoleic
acid. Under challenge conditions with 0.1 mM hexadecenoic acid,
95 proteins were significantly (P#0.05) up-regulated $2-fold and 7
proteins were significantly (P#0.05) down-regulated $2-fold.
MALDI-MS was used to identify 63 of the most intense protein
spots on the gel corresponding to proteins that were modulated by
linoleic acid and the identities of 56 up-regulated and 5 down-
regulated proteins were unambiguously determined (Table 11 and
12). Many of the same proteins, or different proteins within the same
metabolic pathways e.g. glycolysis and pyruvate metabolism, were
identified after exposure to hexadecenoic acid and linoleic acid. This
indicates that there is commonality in the metabolic response to the
cellular perturbations caused by exposure to these LC-uFFAs, which
differ in chain length, and the number and position of double bonds.
Table 4. MRSA252 genes down-regulated during growth in the presence of linoleic acid (0.01mM ) (linoleic acid growth exposure).
Group
Functions
MRSA252
ORF
MRSA252
Gene MRSA252 Gene Product
Fold Change
Down Regulated P-value
Stess Response SAR0525 ctsR stress regulatory protein 3.57 6.52E-05
SAR0526 uvrB/uvrC domain protein 4.35 4.16E-06
SAR0528 clpC putative stress response-related Clp ATPase 4.17 5.47E-05
SAR0823 clpP putative ATP-dependent Clp protease proteolytic subunit 2.04 3.82E-04
SAR0938 clpB putative ATPase subunit of an ATP-dependent protease 9.09 5.72E-06
SAR1657 dnaK chaperone protein 2.94 5.41E-05
SAR1658 grpE GrpE protein 3.57 7.03E-08
SAR2116 groEL 60 kDa chaperonin 2.44 1.05E-03
SAR2117 groES 10 kDa chaperonin 2.78 1.92E-04
Metabolism SAR0189 putative thiamine pyrophosphate enzyme 2.94 1.51E-04
SAR0208 putative sugar transport system permease 2.94 2.68E-02
SAR0209 putative oxidoreductase 4.75 1.21E-02
SAR0210 putative oxidoreductase 9.09 3.75E-03
SAR0527 putative phosphotransferase 4.55 7.03E-08
SAR0752 putative phosphofructokinase 2.44 3.20E-02
SAR0753 fruA fructose-specific PTS system component 3.45 1.21E-02
SAR1274 glpF putative glycerol uptake facilitator protein 3.70 3.36E-03
SAR1275 glpK glycerol kinase 4.17 6.42E-04
SAR1276 glpD glycerol-3-phosphate dehydrogenase 7.69 4.83E-06
SAR2244 mtlA mannitol-specific PTS system component 2.08 4.75E-02
SAR2445 hrtA Heme-regulated transporter ATPase 2.94 3.11E-04
SAR2594 ABC transporter ATP-binding protein 2.33 3.32E-03
Hypothetical GenesSAR0100 putative membrane protein 2.56 2.28E-02
SAR0211 conserved hypothetical protein 11.11 3.02E-03
SAR0584 vraX predicted role in ipenimen resistance 2.27 3.15E-02
SAR0750 conserved hypothetical protein 2.22 1.32E-02
SAR0939 LysR family regulatory protein 2.94 5.81E-05
SAR2595 putative membrane protein 2.04 7.18E-03
doi:10.1371/journal.pone.0004344.t004
S. aureus Response to LC-uFFAs
PLoS ONE | www.plosone.org 14 February 2009 | Volume 4 | Issue 2 | e4344Identification of survival mutants
Allelic replacement mutants were constructed in the genes sasF
and arcA, whichdisplayed altered transcription inresponsetolinoleic
acid and a further mutant was constructed in vraS, encoding a cell
wall synthesis regulator. The contribution of these genes to survival
in the presence of LC-uFFAs was tested on agar plates containing
linoleic acid. Additionally, existing mutants of genes identified by
microarray analysis to display altered transcription in response to
linoleicacid,orregulatorsofthesegenes,weretested.Furthermore,a
5,000 clone Tn917 mutant library was also screened to identify
survival mutants. Analysis of the mutant clones was performed in
SH1000 since MRSA252 is resistant to most antibiotics used for
gene inactivation studies. Importantly, many of the mutant strains
tested exhibited increased sensitivity to LC-uFFAs when compared
to the wild-type, including those harbouring mutations in the genes:
sasF (Liv694), crtM (Liv681), arcA (Liv692), sigB (Liv130), agr (Liv038)
and sarA (Liv039) (Fig. 2A, 2B). In contrast clfA (Liv442), vraS
(Liv718), katA (Liv750), lytSR (Liv101) and clpC (Liv671) did not
contribute to survival under the conditions tested in a SH1000
background. Screening of the Tn917 transposon library identified
two further clones with defective survival. Sequencing upstream and
downstream of the transposon in these mutants revealed insertion of
Tn917 in the SAR2632 (Liv766) and vraE (Liv753) genes.
Complementation of the fatty acid sensitivity of the sasF, arcA, vraE
and SAR2632 mutants was achieved by individually cloning each
gene into the low copy number shuttle vector pSK5630 [75] and
transforming each mutant with the relevant plasmid. Complemen-
tation restored survival of each mutant in LC-uFFA resistance assays
(data not shown).
Autolysis assays
Cells grown in the presence of linoleic acid under constant
growth conditions displayed reduced expression of the CtsR
regulon, which is known to impact on cell autolysis [47].
Consequently we addressed the impact of the presence of LC-
uFFAs upon autolysis of treated and control cells of MRSA252
and SH1000. A significantly increased rate of autolysis was
observed in linoleic acid treated cells of each strain (Fig. 3A, 3B).
This increase is in accordance with the reduced expression of the
CtsR regulon in treated cells.
Cell hydrophobicity
IsdA reduces cell surface hydrophobicity and acts to increase
staphylococcal resistance to LC-uFFAs [34] while a GML resistant
mutant of Enterococcus faecalis was found to be less hydrophobic than
thewild typeparentstrain[48]. Partitioningof cellsinthenon-polar
solvent hexadecane was measured to determine whether modulat-
ing cell hydrophobicity was a S. aureus response to growth in the
presence of fatty acids. Growth in the presence of 0.1 mM linoleic
acid resulted in both strains exhibiting decreased partitioning
indicating a decrease in cell surface hydrophobicity (Fig. 3C). The
change in cell hydrophobicity was particularly dramatic for
MRSA252 with partitioning reduced from over 90% to less than
20% of cells upon growth in the presence of linoleic acid. The
adaptive decrease in cell hydrophobicity makes conditions less
favourable for interactions between the cell and the amphipathic
fatty acid. Alterations to cell surface charge via the dlt and mprF loci
have also been linked to S. aureus evasion of a number of innate
immune system components including cationic antimicrobial
Table 5. MRSA252 genes up-regulated during growth in the presence of oleic acid (0.01 mM) (oleic acid growth exposure).
Group
Functions MRSA252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change Up
Regulated P-value
Virulence Factors
and Regulators
SAR0279 esxA virulence factor EsxA 3.20 1.51E-05
SAR0280 esaA putative membrane protein 2.67 1.07E-04
SAR2122 hld delta-hemolysin precursor 6.02 5.53E-04
SAR2123 agrB putative autoinducer processing protein 6.54 3.55E-07
SAR2125 agrC autoinducer sensor protein 3.77 9.89E-05
SAR2126 agrA autoinducer sensor protein response regulator protein 2.01 2.21E-04
agrIII agrIII Class III accessory gene regulator (agr) locus 6.30 1.12E-07
RNAIII RNAIII RNAIII accessory gene regulator (agr) locus 7.02 3.21E-05
Metabolism SAR0753 fruA fructose-specific PTS system component 2.07 1.34E-02
SAR2296 alsD conserved hypothetical protein 2.05 4.08E-03
SAR2297 alsS putative acetolactate synthase 2.49 1.19E-03
SAR2711 arcC carbamate kinase 4.09 6.41E-03
SAR2712 arcD arginine/ornithine antiporter 3.55 7.34E-04
SAR2713 arcB putative ornithine carbamoyltransferase 3.41 1.97E-03
SAR2714 arcA arginine deiminase 4.03 3.28E-03
Hypothetical
Genes
SAR0277 putative exported protein 2.00 7.31E-03
SAR0301 putative membrane protein 2.15 2.54E-02
SAR0385 putative membrane protein 2.88 8.02E-03
SAR0839 putative lipoprotein 2.07 1.97E-03
SAR1448 major facilitator superfamily 2.03 1.32E-02
SAR2710 putative regulatory protein 2.62 6.93E-05
doi:10.1371/journal.pone.0004344.t005
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Group
Functions MRSA252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change
Down Regulated P-value
Stress Response SAR0525 ctsR stress regulatory protein 3.23 3.26E-05
SAR0526 uvrB/uvrC domain protein 4.17 3.26E-05
SAR0527 putative phosphotransferase 3.85 2.20E-07
SAR0528 clpC putative stress response-related Clp ATPase 3.23 1.01E-04
SAR0938 clpB putative ATPase subunit of an ATP-dependent protease 8.33 1.30E-06
SAR1119 uvrC putative excinuclease ABC subunit C 3.70 7.00E-03
SAR1657 dnaK chaperone protein 2.63 1.01E-04
SAR1658 grpE GrpE protein 2.86 4.78E-06
SAR2116 groEL 60 kDa chaperonin 2.38 1.82E-03
SAR2117 groES 10 kDa chaperonin 2.44 2.21E-04
Metabolism SAR0120 putative ornithine cyclodeaminase 2.38 4.46E-02
SAR0354 putative homocysteine S-methyltransferase 2.13 1.60E-02
SAR0452 putative NADH-Ubiquinone protein 2.00 1.32E-02
SAR1274 glpF putative glycerol uptake facilitator protein 4.35 9.16E-03
SAR1275 glpK glycerol kinase 3.57 1.59E-02
SAR1276 glpD aerobic glycerol-3-phosphate dehydrogenase 4.76 3.26E-05
SAR1849 proline dehydrogenase 3.23 8.02E-03
SAR2445 hrtA Heme-regulated transporter ATPase 2.94 1.01E-04
SAR2446 hrtB Heme-regulated transporter permease 2.22 3.98E-02
SAR2582 gntP putative gluconate permease 5.88 4.53E-03
SAR2583 gntK putative gluconokinase 4.55 3.60E-02
Hypothetical
Genes
SAR0939 LysR family regulatory protein 2.86 2.76E-04
SAR2581 hypothetical protein 4.55 3.99E-02
doi:10.1371/journal.pone.0004344.t006
Table 7. qRT-PCR analysis of gene expression in MRSA252.
ORF Gene Linoleic Challenge Linoleic Growth Oleic Growth Linoleic Growth Oleic Growth
OD600=3 OD 600=3 OD 600=8 OD 600=8
SAR0114 spa 1.46 (0.37) 1.01 (0.07) 21.08 (0.11) 23.03 (0.14) 22.92 (0.24)
SAR0223 fadA 3.10 (0.08) nd nd nd nd
SAR0225 fadD 3.16 (0.61) 21.34 (0.03) 21.88 (0.02) 21.06 (0.03) 21.01 (0.02)
SAR0258 lytR 25.03 (0.01) nd nd nd nd
SAR0625 sarA 3.84 (0.81) 1.10 (0.11) 21.12 (0.07) 1.52 (0.55) 2.05 (1.12)
SAR2621 cidA 21.93 (0.02) 1.52 (0.03) 1.41 (0.03) 22.75 (0.01) 21.39 (0.02)
SAR0938 clpB 3.90 (0.08) 28.55 (0.01) 210.31 (0.01) 23.16 (0.01) 23.00 (0.01)
SAR0978 fabI 1.25 (0.02) nd nd nd nd
SAR1136 hla 21.60 (0.20) 1.19 (0.19) 21.71 (0.09) 6.38 (2.91) 7.88 (5.16)
SAR1344 katA 7.27 (0.18) nd nd nd nd
SAR1430 murG 7.59 (0.22) nd nd nd nd
SAR2187 fabZ 3.37 (0.64) 21.10 (0.02) 1.40 (0.02) 1.10 (0.04) 1.20 (0.06)
SAR2643 crtM 3.72 (0.08) nd nd nd nd
SAR2714 arcA 1.61 (0.03) 1.86 (0.04) 2.17 (0.04) 22.19 (0.02) 21.50 (0.01)
SAR2725 sasF 31.86 (0.69) nd nd nd nd
RNAIII 7.86 (0.15) 56.14 (1.40) 34.28 (0.74) 156.12 (6.95) 153.30 (2.81)
The values correspond to the fold change for each gene tested under the relevant fatty acid treatment conditions when compared to the untreated control. The standard
deviation for each measurement is in parentheses. nd, not detemined. ORF indicates the gene locus in MRSA252 (http://www.genedb.org/genedb/saureusMRSA/).
doi:10.1371/journal.pone.0004344.t007
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identified in this study as having decreased survival upon exposure
to linoleic acid, did not exhibit altered hydrophobicity in this
partitioning assay (data not shown). This indicates that the products
of these three genes interact with LC-uFFAs in a manner that does
not involve alterations to cell surface hydrophobicity.
Murine arthritis virulence assay
A murine arthritis model of infection was used to determine a role
for the LC-uFFA survival genes sasF and vraE in pathogenesis. This
model of infection also reports on systemic inflammation and abscess
formation in kidneys and was therefore relevant for in vivo
investigation of fatty acid survival mutants. Neither the sasF nor vraE
mutations showed a significant reduction in arthritis development of
SH1000 in this model (data not shown). However, a significantly
reduced weight loss (P,0.05) was observed for both sasF and the vraE
mutants for 3 out of 5 weight measurements over the 14 day
experiment, when compared to the SH1000 parent strain (Fig. 4A).
In contrast, while a reduced bacterial load of both mutant strains was
observed in the kidney compared to the wild type this was not found
to be significant (p=0.075) (Fig. 4B). Collectively, these data suggest
that SasF and VraE might make contributions to the pathogenesis of
systemic inflamation, but not to the development of arthritis.
Discussion
Analysing the response of MRSA252, an EMRSA-16 clone, to
the LC-uFFAs linoleic [C18:2 (n-6,9)] and oleic [C18:1 (n-6)] acid
revealed modulated expression of many genes, including those
encoding virulence determinants. After exposure of exponentially
growing cells to linoleic acid there was a very large increase in
RNAIII compared to control cells, and this was also observed at all
stages of growth when either linoleic or oleic acid were present
from the time of inoculation. This observed up-regulation of
RNAIII synthesis was unexpected given previous reports on the
effects of GML, a lauric acid monoester, and the LC-uFFA
hexadecenoic acid [C16:1 (n-6)] on S. aureus gene expression
[34,35]. In those studies, there was no change in agr (RNAIII)
expression, but down-regulation of agr-regulated virulence deter-
minants, including alpha toxin (hla). MRSA252 has a nonsense
mutation in hla, which does not affect hla mRNA measurements by
qRT-PCR but ablates activity of the encoded protein preventing
activity measurements [52]. In this study, transcription of hla in
MRSA252 was only up-regulated in the presence of linoleic or
oleic acid in the post-exponential growth phase demonstrating
maintenance of its temporal expression, despite up-regulation of
RNAIII at earlier phases of growth. Analysis by qRT-PCR
revealed contrasting regulation of RNAIII synthesis in SH1000
and MRSA252 in response to treatment with LC-uFFAs. RNAIII
levels were reduced after growth exposure to linoleic or oleic acid
during growth of SH1000. The data reported here therefore
highlights important differences between the effects of these LC-
FFAs between strains. Previous studies identified a fatty acid
modifying enzyme (FAME) in strains of S. aureus, which esterifies
LC-FFAs with cholesterol, thereby reducing toxicity [32].
However, this activity was demonstrated to be agr-regulated
[29,53], producing the anomaly that in strains with SH1000-like
regulation, expression of the detoxifying enzyme would be down-
regulated upon exposure to its substrate. MRSA252 is a successful
epidemic strain of S. aureus and the ability to persist in an
environment containing LC-uFFAs such as on the skin surface
(hexadecenoic acid) or in skin infections (linoleic and oleic acid)
would aid the transmission of the organism. In this scenario, the
specific up-regulation of agr in response to LC-uFFAs observed in
MRSA252 (EMRSA-16) may contribute towards its success as an
epidemic strain. Superior skin colonisation was previously
suggested as a reason for the epidemic nature of the EMRSA-15
and -16 strains, which together are responsible for over 95% of
MRSA from cases of nosocomial bacteraemia in the UK [54,55].
Microarray analysis revealed further virulence factors exhibiting
increased transcription, including the esx locus, which encodes a
specific secretion system and the ESAT-6-like proteins that have
been confirmed as having a role in the pathogenesis of murine
abscesses [41]. Increased transcription of the esx locus was only
observed after growth exposure to linoleic or oleic acid and not in
response to linoleic acid challenge conditions. Increased transcrip-
tion of the arcABDC operon, encoding the arginine deiminase
(ADI) pathway enzymes, was observed under the same conditions
where the esx locus is up-regulated. The ADI pathway enables the
utilisation of arginine as an energy source under anaerobic
conditions of growth. Concomitant with the expression of the ADI
pathway, there was an up-regulation of many glycolytic enzymes,
suggesting that a net effect of growth exposure to linoleic acid was
metabolic alterations leading toward anaerobic growth. To test the
importance of the ADI pathway under these conditions, an arcA
allelic replacement mutant of SH1000 was generated (arcA was
transcriptionally up-regulated in both SH1000 and MRSA252).
The arcA strain was found to display a reduction in growth on agar
plates containing 1 mM linoleic acid, with a 25-fold lower survival
than the parental strain. The alteration in metabolism via up-
regulation of the ADI pathway is therefore important for survival
under these conditions. The ADI pathway may also contribute to
virulence since some ST8-SCCmecIVa (USA300) MRSA clones
carry the arginine catabolism mobile element (ACME), which
contains an extra copy of the arc operon [56]. This leads to the
hypothesis that the arcABDC operon facilitates pathogenicity by
increasing survival of S. aureus in the presence of LC-uFFAs.
The sasFgeneshowedthelargestchangeinexpressionofanygene
in response to linoleic acid challenge (.16-fold and .30-fold up-
regulation in MRSA252 by microarray and qRT-PCR, respective-
ly). Expression of SasF, an LPXAG motif cell wall-anchored surface
protein, is repressed by TcaR, the teicoplanin-associated locus
Table 8. qRT-PCR analysis of gene expression in SH1000.
ORF Gene
Linoleic
Challenge
Linoleic
Growth Oleic Growth
OD600=3 OD 600=3
SAR0114 spa 2.19 (0.09) 21.94 (0.02) 1.66 (0.04)
SAR0258 lytR 22.31 (0.02) nd nd
SAR0625 sarA 1.26 (0.05) 23.79 (0.02) 23.45 (0.03)
SAR0938 clpB 1.95 (0.08) 22.11 (0.02) 22.58 (0.03)
SAR0978 fabI 21.20 (0.04) nd nd
SAR1136 hla 23.60 (0.01) 22.11 (0.02) 22.58 (0.03)
SAR1430 murG 1.84 (0.11) nd nd
SAR2643 crtM 1.32 (0.05) nd nd
SAR2714 arcA nd 2.19 (0.10) 4.39 (0.18)
SAR2725 sasF 1.49 (0.06) nd nd
RNAIII 21.79 (0.03) 23.29 (0.01) 21.95 (0.01)
The values correspond to the fold change for each gene tested under the
relevant fatty acid treatment conditions when compared to the untreated
control. The standard deviation for each measurement is in parentheses. nd, not
detemined. ORF indicates the gene locus in MRSA252 (http://www.genedb.org/
genedb/saureusMRSA/) that was tested in SH1000.
doi:10.1371/journal.pone.0004344.t008
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be up-regulated (.3-fold) in MRSA252 under the linoleic challenge
conditions (Table 1). However, the SH1000 strain harbours a
truncated copy of tcaR [42,58] and synthesises a non-functional
protein. This could explain why the sasF gene was only slightly up-
regulated in SH1000 since its transcription may already be very high
as its expression is reduced as part of the TcaR regulon. Many of the
differences observed in the transcriptional responses of SH1000 and
MRSA252 to the presenceoffatty acids (Table 7, 8) are thus likely to
be due to differential responses modulating RNAIII production,
altered sarA transcription and differences between the strains in
respect of the functionality of TcaR. The importance of sasF
transcription for adaptation and survival of S. aureus to linoleic acid
was tested by constructing an allelic replacement mutant in SH1000.
Table 9. MRSA252 proteins up-regulated following the addition of linoleic acid (0.1 mM) to exponentially growing cells (linoleic
acid challenge).
Group Functions MRSA252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change
Up Regulated P-value
Virulence Factors
and Regulators
SAR2745 capA Capsular polysaccharide biosynthesis protein 3.36 2.27E-04
Energy Metabolism SAR0140 deoC1 deoxyribose-phosphate aldolase 4.34 2.49E-03
SAR0217 formate acetyltransferase 2.30 1.50E-03
SAR0394 phosphoglycerate mutase family protein 2.94 1.67E-02
SAR0828 gap1 glyceraldehyde 3-phosphate dehydrogenase 1 2.07 3.53E-03
SAR0924 pgi glucose-6-phosphate isomerase 4.18 7.43E-03
SAR1451 ald2 alanine dehydrogenase 2 2.13 1.32E-03
SAR1789 ackA acetate kinase 2.81 6.97E-04
SAR2506 dpgm putative phosphoglycerate mutase 2.15 3.52E-02
SAR2685 mqo2 malate:quinone oxidoreductase 3.39 8.08E-03
DNA Repair and
Replication
SAR1639 dnaG DNA primase 2.66 2.61E-03
SAR1996 lig DNA Ligase 2.09 6.11E-04
Protein Synthesis SAR0552 fus elongation factor G 4.47 2.51E-04
SAR0552 fus elongation factor G 2.10 2.09E-02
SAR1216 trmD putative tRNA (guanine-7-)-methyltransferase 2.33 4.84E-04
SAR1720 queA S-adenosylmethionine:tRNA ribosyltransferase-isomerase 2.11 1.68E-02
SAR2309 rpoA RNA polymerase alpha subunit 2.61 2.40E-03
Peptidoglycan
Synthesis
SAR0470 lysR family regulatory protein 2.20 1.07E-02
SAR1762 thrS threonyl-tRNA synthetase 2.77 9.07E-04
SAR1991 gatB aspartyl/glutamyl-tRNA amidotransferase subunit B 2.25 3.52E-02
SAR2201 glyA serine hydroxymethyltransferase 3.55 8.43E-03
SAR2201 glyA serine hydroxymethyltransferase 2.15 3.74E-03
Carotenoid
Biosynthesis
SAR1378 prephenate dehydrogenase 2.37 8.08E-03
Miscellaneous SAR0218 putative pyruvate formate-lyase activating enzyme 2.60 3.46E-02
SAR0403 putative DNA binding protein 2.72 3.48E-02
SAR2007 putative oxygenase/mitric oxide synthase 2.04 7.13E-03
SAR2007 putative nitric oxide synthase 2.66 2.38E-02
Metabolism SAR0150 adhE putative aldehyde-alcohol dehydrogenase 3.48 5.07E-03
SAR0246 ispD 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase 2.43 4.84E-04
SAR0246 ispD 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase 2.21 8.75E-03
SAR0564 putative haloacid dehalogenase-like hydrolase 2.22 1.01E-02
SAR1070 pdhD dihydrolipoamide dehydrogenase 2.22 2.62E-02
SAR2353 mobA molybdopterin-guanine dinucleotide biosynthesis protein 3.12 8.32E-04
SAR2513 6-carboxyhexanoate–CoA ligase 4.84 4.13E-05
SAR2641 putative aminotransferase 2.07 1.54E-02
Hypothetical ProteinsSAR0985 putative RNA ligase protein 2.31 2.12E-02
SAR2064 hypothetical phage protein 2.06 1.41E-03
SAR2369 Acyl-CoA dehydrogenase-related protein 3.36 4.69E-03
doi:10.1371/journal.pone.0004344.t009
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containing 1 mM linoleic acid, exhibiting a 6-fold lower level of
survival than the parental strain (Fig. 2A). The expression of this cell
wall-anchored protein is therefore important for survival under these
conditions. SasF may also contribute to virulence since in a murine
arthritis model of infection a sasF allelic replacement mutant of
SH1000caused significantlylessweightlossoftheanimalscompared
to control cells (Fig. 4A). Reduced numbers of bacteria were
harvested from the kidney in mice infected with the sasF mutant
strain compared to the control but the difference was not significant
(Fig. 4B). SasF did not significantly affect development or severity of
arthritis.
A screen for additional mutants of SH1000 that were defective
for survival in the presence of linoleic acid identified several Tn917
transposants from a 5,000 clone library of mutants. Sequencing
located the transposons within genes encoding VraE (ABC
transporter permease) and SAR2632 (MMPL domain, putative
efflux pump). The mutants Liv753 (vraE) and Liv766 (SAR2632)
had reduced survival using this agar plate-based assay exhibiting
130-fold and 4-fold reductions in viability, respectively, at 1 mM
linoleic acid (Fig. 2A). Each of these genes encodes transporter
proteins of unknown function. The gene vraE is located
downstream of vraD in a bicistronic operon and is a member of
the GraSR regulon proposed to regulate traffic of cell wall
substrates [59,60]. Two studies have shown that S. aureus vraE
mutants display decreased resistance to meticillin and increased
susceptibility to human b-defensin 3. [61,62]. VraE may also
contribute to virulence, since in a murine arthritis model of
infection a vraE allelic replacement mutant of SH1000 resulted in
significantly less weight loss of the animals compared to control
cells (Fig. 4A). Reduced numbers of bacteria were harvested from
the kidney in mice infected with the vraE mutant strain compared
to control but the difference was not significant (Fig. 4B). VraE did
not significantly affect the development or severity of arthritis (data
not shown). SAR2632 is a predicted transporter protein of the
MMPL domain family proposed to be involved in lipid transport
[63].
The identification of cell envelope mutants correlated with the
gene expression and proteomic data, in which altered levels of cell
wall synthesis and regulation components was observed (Fig. 5A).
An increase in autolysis was observed under growth exposure
conditions, although whether this is due to changes in expression
of PG synthesis genes or down-regulation of the CtsR regulon
remains unelucidated. The overall up-regulation of many cell wall
synthesis genes could have two possible explanations. Firstly, the
increased synthesis may be required to maintain the integrity of
the cell wall, damaged due to loss of material through the
precipitation of PG by LC-uFFAs as described by Campbell et al.
[25]. The binding of LC-uFFAs to PG would not be unexpected
given that chitosan, which has a very similar structure to PG, has
been shown to bind lipids [64]. Secondly, an increase in cell wall
and capsule synthesis could act as a defense mechanism since an
increase in ionically charged material surrounding the cell would
mitigate against access of the non-polar carbon chain of LC-uFFAs
to the cell membrane. Reduced cell surface hydrophobicity and
increased thickness of the cell wall have been suggested as Gram-
positive defense mechanisms to limit interactions with lipids
[34,48]. Therefore, the reduced cell surface hydrophobicity of
both the MRSA252 and SH1000 strains, observed here following
overnight growth in the presence of linoleic acid, represents a
pathogen countermeasure to this component of the innate
immune system.
Previous studies have used gene expression profiling to
determine the cellular pathway targeted by antimicrobial agents
[65,66]. In this study, there was no change in expression of fatty
acid biosynthesis genes, other than fabZ, which is located on the
same operon as the PG synthesis gene murA1. This suggests that
the anti-staphylococcal toxicities of the LC-uFFAs used in this
study are not a consequence of inhibiting fatty acid biosynthesis.
Prior studies on the action of LC-uFFAs upon cells of S. aureus
demonstrated membrane perturbations [12,18,22,26]. This sup-
ports the finding of Chamberlain et al. that increased fluidity of S.
aureus membranes resulted from exposure to LC-uFFAs [26].
Furthermore, these authors demonstrated that carotenoid-depen-
dent pigmentation in non-isogenic clinical isolates positively
correlated with increased survival from LC-uFFAs and showed
that the carotenoid staphyloxanthin acted to decrease membrane
fluidity and reduce its damaging effects. Interestingly, genes
involved in carotenoid biosynthesis were up-regulated in response
to LC-uFFAs (Fig. 5B), and Liv681 (crtM), which cannot produce
staphyloxanthin, was shown here to have a .5-fold reduced
survival to 1 mM linoleic acid. Staphyloxanthin production is
regulated via s
B, which also regulates many stress response
components observed to be up-regulated in the array data.
Consequently, the general stress response, including the produc-
tion of staphyloxanthin serves as an important component of
defence against LC-uFFAs, given the discovery that Liv130 (sigB)
exhibited a .75-fold reduction in survival to 1 mM linoleic acid.
sigB has previously been shown to contribute to S. aureus resistance
to antimicrobials [67]. The CtsR regulon was strongly up-
regulated after linoleic acid challenge, but was down-regulated
after growth exposure and may therefore also participate in the
adaptation to this environment.
A consequence of LC-uFFAs inserting in the cell membrane
could be the disruption of the electron transport chain. This would
explain the numerous changes in expression of genes associated
Table 10. MRSA252 proteins down-regulated following the addition of linoleic acid (0.1 mM) to exponentially growing cells
(linoleic acid challenge).
Group
Functions MRSA252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change Down
Regulated P-value
Protein Synthesis SAR0927 spsB signal peptidase Ib 5.88 9.88E-04
SAR1755 tig trigger factor 2.56 1.93E-02
SAR2179 putative membrane protein 2.17 2.05E-02
Peptidoglycan Synthesis SAR1284 glnA glutamine synthetase 2.33 5.00E-02
Metabolism SAR0814 hprK kinase/phosphorylase 3.03 6.66E-03
doi:10.1371/journal.pone.0004344.t010
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(hexadecenoic acid challenge).
Group
Functions MRSA252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change
Up regulated P-value
Stress Response SAR2116 groEL chaperonin 2.03 3.49E-02
SAR2273 asp23 alkaline shock protein 23 2.89 8.90E-03
SAR2461 pyridine nucleotide-disulphide oxidoreductase family protein 2.05 3.99E-02
SAR2461 pyridine nucleotide-disulphide oxidoreductase family protein 2.00 2.13E-03
SAR2461 pyridine nucleotide-disulphide oxidoreductase family protein 2.59 2.49E-02
Energy Metabolism SAR0140 deoC1 deoxyribose-phosphate aldolase 4.21 4.86E-03
SAR0394 phosphoglycerate mutase family protein 4.79 1.06E-03
SAR0828 gap1 glyceraldehyde 3-phosphate dehydrogenase 1 2.86 2.51E-03
SAR0830 tpiA triosephosphate isomerase 3.40 4.42E-03
SAR0832 eno enolase 3.20 1.83E-02
SAR0832 eno enolase 3.09 4.60E-03
SAR0832 eno enolase 2.07 5.15E-03
SAR0924 pgi glucose-6-phosphate isomerase 2.31 2.73E-02
SAR1068 pdhB putative pyruvate dehydrogenase E1 component 2.72 2.29E-04
SAR1068 pdhB putative pyruvate dehydrogenase E1 component 2.72 2.29E-04
SAR1121 sdhA putative succinate dehydrogenase flavoprotein 2.24 1.36E-02
SAR1451 ald2 alanine dehydrogenase 2 2.21 2.30E-03
SAR2605 ddh D-lactate dehydrogenase 3.11 8.87E-03
SAR2685 mqo2 malate:quinone oxidoreductase 4.79 1.06E-03
SAR2685 mqo2 malate:quinone oxidoreductase 3.13 2.18E-03
DNA Repair and
Replication
SAR1997 pcrA ATP-dependent DNA helicase 2.23 3.49E-02
Protein Synthesis SAR0552 fus translation elongation factor G 3.56 3.84E-02
SAR0553 tuf translation elongation factor Tu 2.65 3.41E-02
SAR0553 tuf elongation factor Tu 4.13 7.56E-03
SAR1216 trmD putative tRNA (guanine-7-)-methyltransferase 2.80 1.69E-03
SAR1485 rpsA putative 30S ribosomal protein S1 2.91 4.91E-02
SAR1719 tgt queuine tRNA-ribosyltransferase 2.01 4.96E-02
SAR1720 queA S-adenosylmethionine:tRNA ribosyltransferase-isomerase 2.49 1.44E-02
SAR2309 rpoA DNA-directed RNA polymerase subunit alpha 2.44 9.73E-03
Peptidoglycan
Synthesis
SAR1048 purD putative phosphoribosylamine–glycine ligase 3.98 2.08E-02
SAR1762 thrS threonyl-tRNA synthetase 2.51 1.51E-02
SAR2212 murA2 UDP-N-acetylglucosamine 1-carboxyvinyltransferase 2.13 1.36E-02
Cell Division SAR1795 ezrA putative septation ring formation regulator 3.11 3.71E-03
SAR1795 ezrA putative septation ring formation regulator 2.56 5.16E-03
Miscellaneous SAR0218 putative pyruvate formate-lyase activating enzyme 2.39 4.03E-03
SAR0403 putative DNA-binding protein 2.84 8.32E-03
SAR2007 putative oxygenase 2.85 2.92E-02
Metabolism SAR0351 thl acetyl-CoA acetyltransferase 2.85 2.59E-04
SAR0351 thl acetyl-CoA acetyltransferase 2.77 9.07E-04
SAR0514 putative O-acetylserine (thiol)-lyase 2.41 4.43E-03
SAR1142 otc ornithine carbamoyltransferase 2.03 5.43E-03
SAR2352 moaA putative molybdenum cofactor biosynthesis protein A 3.73 6.34E-03
SAR2352 moaA putative molybdenum cofactor biosynthesis protein A 2.25 9.64E-03
SAR2460 putative acetyltransferase (GNAT) family protein 5.37 6.22E-05
SAR2460 putative acetyltransferase (GNAT) family protein 5.20 2.03E-02
SAR2641 putative aminotransferase 2.12 8.47E-03
SAR2694 nrdG putative anaerobic ribonucleotide reductase activating protein 3.38 4.66E-04
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constitute the main cellular response to LC-uFFAs. The overall
trend is one of increasing levels of pyruvate and alterations in
menaquinone synthesis. Moreover, the ADI pathway for anaer-
obic utilisation of arginine was up-regulated under growth
exposure conditions. The genes affected by LC-uFFAs include
those involved in the glycolytic and fermentative pathways, cell
wall synthesis, cell division, and capsule synthesis. These
pathways have also been shown to be modulated in a S. aureus
small colony variant, which has a mutation in the hemB gene of
the electron transport chain [68]. This supports a mode of action
for LC-uFFAs of disturbing cell energetics via membrane
disruption. Finally, the overall similarities in responses to the
LC-uFFAs employed in this study appear to indicate a common
mode of action amongst the linoleic, oleic and hexadecenoic
acids. This corroborated dataset on the transcriptional and
translational responses of S. aureus should provide a useful resource
for further studies on this pathogens response to the host
environment.
Materials and Methods
Bacterial strains, plasmid and growth conditions
Strains and plasmids used in this study are listed in Table 13.
Unless indicated otherwise, bacteria were grown in brain heart
infusion broth (BHI)(Merck) at 37uC with shaking at 125 rpm.
When included, antibiotics were added at the following concen-
trations: erythromycin, 5 mgm l
21; lincomycin, 25 mgm l
21;
tetracycline, 5 mgm l
21, chloramphenicol 10 mgm l
21.
Transposon mutagenesis and screening for sensitivity to
LC-uFFAs
Transposon mutagenesis was performed on the SH1000 strain of
S. aureus using the Tn917 containing plasmid pLTV1, as described
previously [69]. Single colonies from a transposon library grown on
BHI agar containing erythromycin and lincomycin were innoculated
into 96-well plates containing 200 ml of BHI. From this library 5,000
clones were cultured and stored at 280uCi n1 0 %g l y c e r o l .A f t e r
repeat growth of clones overnight at 37uC, without shaking, cultures
were diluted 100-fold before 5 ml was spotted onto BHI agar with or
without 0.5 mM linoleic acid. After overnight incubation, strains with
decreased resistance to linoleic acid, when compared to wild type
(WT) SH1000, were selected. The transposon-mediated mutations in
these strains were transduced into the WT SH1000 using ø11 as
described previously [70]. The linoleic acid sensitivity of these
mutants was reconfirmed, proving the phenotype was transposon-
linked, by repeat assay using serial dilutions of the mutant strains onto
BHI agar containing millimolar concentrations of linoleic acid. The
locations of the Tn917 insertions within the genome of mutants were
determined usingarbitrary primed nested PCRand DNAsequencing
of regions upstream and downstream of the transposon [71].
Construction of sasF, arcA and vraS insertional mutants
and complementation plasmids
Construction of sasF, arcA and vraS mutants was performed as
described by Horsburgh et al. [72] using the oligonucleotides
describedinTable14.Brieflythiswasasfollows:thesasF,arcAor vraS
genes were amplified as upstream and downstream fragments using
Group
Functions MRSA252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change
Up regulated P-value
SAR2694 nrdG putative anaerobic ribonucleotide reductase activating protein 2.48 3.43E-02
Hypothetical Proteins SAR0246 ispD 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase 3.37 2.20E-04
SAR0246 ispD 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase 2.90 1.69E-03
SAR0985 putative RNA ligase protein 2.11 1.68E-02
SAR1105 isdD hypothetical protein 2.25 3.60E-03
SAR2063 hypothetical phage protein 2.06 1.41E-03
SAR2369 putative acyl-CoA dehydrogenase 2.61 2.43E-04
SAR2545 M42 glutamyl aminopeptidase 2.08 1.72E-02
SAR2674 hypothetical protein 2.45 5.46E-04
doi:10.1371/journal.pone.0004344.t011
Table 11. Cont.
Table 12. MRSA252 proteins down-regulated following the addition of hexadecenoic acid (0.1 mM) to exponentially growing cells
(hexadecenoic acid challenge).
Group
Functions MRSA252 ORF MRSA252 Gene MRSA252 Gene Product
Fold Change
Down Regulated P-value
Protein Synthesis SAR0927 spsB signal peptidase Ib 4.55 8.44E-03
Peptidoglycan
Synthesis
SAR0920 NAD-specific glutamate dehydrogenase 2.17 8.21E-03
Miscellaneous SAR2622 lysR family regulatory protein 2.13 1.21E-02
Metabolism SAR0483 tmk putative thymidylate kinase 2.27 1.04E-03
SAR1399 pstB ABC transporter ATP-binding protein 3.23 1.80E-03
doi:10.1371/journal.pone.0004344.t012
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arcA_BamHI/arcA_NotIa n da r c A _ KpnI/arcA_EcoRIo rv r a S _
BamHI/vraS_NotI and vraS_KpnI/vraS_EcoRI, respectively. The
tetracycline resistance gene from pDG1513 [73] was amplified by
using the primer pair Tet_NotI/Tet_KpnI. The upstream, down-
stream and tet gene fragments were digested with BamHIa n dNotI, or
KpnIa n dEcoRI, or NotIa n dKpnI, respectively, and simultaneously
ligated into pAZ106, which had been previously digested with
BamHIa n dEcoRI. The resulting constructs were confirmed by
restriction digest and then used to transform electrocompetent S.
aureus RN4220 by the method of Schenk and Ladagga [74]. Strains
of RN4220 containing the Campbell integration of the plasmid were
resolved in SH1000 by transductional outcross using ø11. Clones of
SH1000, which had now lost the plasmid and contained an allelic
replacement with the tetracycline resistance gene, were confirmed as
mutants by PCR amplification. Correct allelic replacement was
confirmed in each case.
Complementation of the sasF, arcA, vraE and SAR2632 mutants
was performed by amplifying each gene with sufficient upstream
and downstream DNA using the primer pairs listed in Table 14.
The fragments were ligated into pSK5630 [75] following digestion
with BamHI/SalI, and the resulting constructs and the control
plasmid were transformed into E. coli DH5a, with selection on
agar plates containing ampicillin. The resulting constructs were
confirmed by restriction digest and then used to transform
electrocompetent S. aureus RN4220. The plasmids were then
Figure 2. Plate based survival assay. A Graph showing the percentage survival of WT and mutant variants of SH1000 when serial dilutions of the
strains were plated on BHI agar containing 1 mM linoleic acid. Survival is expressed as a percentage of viable cell counts obtained for control plates
lacking linoleic acid. Values are the mean of multiple independent experiments. Error bars indicate standard errors of the mean. p,0.005 for each
mutant by Student’s t-test. B Plates showing the relative survival of SH1000 and the sasF (Liv694) and vraE (Liv753) mutants on BHI agar containing 0
or 1 mM linoleic acid. The 10
21 to 10
26 dilution series of cultures are as indicated.
doi:10.1371/journal.pone.0004344.g002
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PLoS ONE | www.plosone.org 22 February 2009 | Volume 4 | Issue 2 | e4344Figure 3. Physiological effects of linoleic acid on S. aureus. The result of growth of MRSA252 and SH1000 in the absence (closed triangle) or
presence (open box) of 0.01mM linoleic acid on autolysis is shown in A and B, respectively. Survival is expressed as a percentage of OD600 at T=0.
Values are from three independent experiments. Error bars indicate standard errors of the mean. **p,0.01, *p,0.05 by Student’s t test. C Relative
hydrophobicity of the MRSA252 and SH1000 strains following overnight growth in BHI +/2 0.1 mM linoleic acid. Values are from three independent
experiments. Error bars indicate standard errors of the mean. **p,0.01, *p,0.05 by Student’s t test.
doi:10.1371/journal.pone.0004344.g003
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mutant strains.
Microarray analysis
To ascertain the transcriptional responses of MRSA252 to fatty
acids, overnight cultures (18 h) of MRSA252 were used to inoculate
100 mlofBHI(Merck) with or without 10 mMofoleicorlinoleicacid
in 250 ml conical flasks. These 100 ml cultures were placed in a
shaking water bath at 37uC at 250 rpm and 10 ml samples were
taken from the flask when the cultures reached late exponential phase
(OD600=3). Identical inoculations were performed to 100 ml of BHI
lacking additional fatty acids. 100 mM of linoleicacidin ethanol or an
equal volume of the ethanol used to dilute the fatty acid was added to
these cultures at an OD600=3.0 and the RNA extracted from treated
and untreated cells 20 min post-treatment. Each treatment and
control culture was performed in biological triplicate. The concen-
trations of fatty acids used in these experiments did not alter the pH of
the media. RNA was extracted from 10 ml samples of culture taken
at the indicated time intervals and stabilised by the addition of 20 ml
of RNA Bacteria Protect (Qiagen). The cells were subsequently
harvested by centrifugation at 5000 rpm for 10 min and cell pellets
resuspended in lysis buffer (10 mM Tris, pH8.0) containing 200 U
ml
21 of lysostaphin and 400 U ml
21 of mutanolysin, and incubated
for 90 min at 37uC with gentle shaking every 10–15 min. The RNA
was subsequently extracted using the RNeasy Midi kit (Qiagen) and
DNase treated whilst on the purification column using the RNase-
Free DNase Set according to manufacturers instructions (Qiagen).
The quantity and quality ofthe RNA wasassessed onan Agilent 2100
bioanalyzer by using the RNA 6000 Nano LabChip Kit. The RNA
was converted to cDNA and labelled by incorporation of Cy5 dCTP
during reverse transcription of RNA using the enzyme Superscript II
(Amersham). DNA used in the microarray hybridisations was
extracted from 5 ml of an overnight culture (18 h) of MRSA252
using the Edge Biosystems Bacterial Genomic DNA purification kit
according to manufacturer’s instructions. The DNA was labeled by
the incorporation of Cy3 dCTP using Klenow (Invitrogen). cDNA
d e r i v e df r o mR N Aa n dg e n o m i cD N Aw e r ep o o l e da n dh y b r i d i z e d
on whole-genome microarrays supplied by the Bacterial Microarray
Group at St. George’s Hospital (BmG@S [http://bugs.sgul.ac.uk])
before washing and scanning [76]. Microarrays were scanned using
an Affymetrix 428 scanner and image data extracted using ImaGene
5.2 (BioDiscovery). Fully annotated microarray data have been
deposited in BmG@Sbase (accession number E-BUGS-68; http://
bugs.sgul.ac.uk/E-BUGS-68) and also ArrayExpress (accession
number E-BUGS-68). Two independent labelling reactions and
hybridisations were carried out for each RNA sample. Image data
was analysed using the GeneSpring 7.3.1 software (Silicon Genetics).
Briefly, data were normalized relative to the corresponding untreated
controls. Signals below 0.01 were taken as 0.01. Genes were then
filtered on expression level to remove non-changing genes, with only
those genes that changed by at least two-fold considered biologically
significant. Changing genes were then filtered on confidence applying
the Benjamini and Hochberg false discovery rate algorithm with a
maximum significance cut-off at 0.05 to eliminate the chance of false-
positives [77].
Quantitative Real-Time PCR
To confirm the validity of microarray data gene specific
mRNAs were quantified from treated and untreated cultures by
quantitative real-time PCR (qRT-PCR). Cells were grown in
biological triplicate exactly as described above for the microarray
experiments and bacterial RNA was isolated using the Pro-Blue
Fast RNA kit (MP Biomedicals). DNA was removed from the
samples by DNase I treatment (Ambion) according to manufac-
turer’s instructions. The purified RNA was quantified using the
nanodrop ND-1000 Spectrophotometer (Thermo Fisher Scientific)
and the integrity assessed by electrophoresis. 0.5 mg of RNA was
reverse transcribed with 100 U of Bioscript Reverse Transcriptase
(Bioline) using 0.2 mg of random hexamer primers (Promega)
according to manufacturer’s instructions. qRT-PCR was per-
formed using the 7500 Fast System (Applied Biosystems) and the
QuantiFast SYBR Green PCR kit (Qiagen) according to
manufacturer’s instructions. The relative levels of gene expression
in fatty acid treated cells and the non-treated controls were
calculated by relative quantification using gyrB as the endogenous
reference gene. The choice of gyrB as a single reference gene was
based on its consistent levels in microarray in all conditions and at
all timpoints that were analysed. The oligonucleotides used for
qRT-PCR are listed in Table 15. All samples were amplified in
triplicate and the data analysis was carried out using the 7500 Fast
System Software (Applied Biosystems).
Sample preparation for 2D-PAGE
Cultures of MRSA252 (100 ml) were grown to late exponential
phase (OD600=3.0) and exposed to 0.1 mM linoleic acid or
0.1 mM hexadecenoic acid as described above. Cells were
harvested by centrifugation at 5000 g for 10 min at 4uC. After
two washes in PBS the cells were resuspended in 2 ml of lysis
buffer (PBS, 1 mg/ml DNase I, 100 mM benzamidine, 100 mM
PMSF, 1 mg/ml RNase, 2 mg/ml lysostaphin) and incubated at
37uC for 20 min before chilling on ice. Cell debris and insoluble
material was pelleted by centrifugation at 4uC for 20,000 g for
20 min. The supernatant was stored at 220uC. Protein samples
Figure 4. Contribution of vraE and sasF to virulence. A Effect of
WT SH1000 (open box) and mutations of vraE (vertical hatched box) and
sasF (diagonal hatched box) on percentage change in weight of
infected mice. *p,0.05, **p,0.01 by Dunn’s test. B Effect of mutations
of vraE (closed triangle) and sasF (closed inverted triangle) on cfu of S.
aureus SH1000 (closed box) in kidneys of infected mice.
doi:10.1371/journal.pone.0004344.g004
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samples were desalted using Slide-A-Lyzer Mini Dialysis Units
with a 3.5 kDa MWCO (Thermo Scientific).
2D-PAGE
Soluble protein (120 mg ) was brought up to 320 ml with
rehydration buffer (8 M urea, 2M thiourea, 4% (w/v) CHAPS,
20 mM DTT, 1% (v/v) ASB 14 detergent and 0.5% (v/v) carrier
ampholytes (Bio-lyte 3/10, Bio-Rad)). Samples were incubated for
an hour at room temperature with gentle shaking, before
centrifugation at 8,000 g for 5 min. Samples were in-gel
rehydrated and focused on 17 cm, pH 4–7 IPG strips (Bio-Rad)
for a total of 40000 V h (150V for 1h, 300V for 1h, 600V for 1h,
1200V for 1h, 1200–8000V over 1h (linear gradient), 8000 V to
40000 v (steady state)), using a Protean IEF Cell (Bio-Rad). After
focusing, strips were equilibrated in 50 mM Tris (pH 6.8), 6 M
urea, 2% (w/v) SDS, 30% (w/v) glycerol, and bromophenol blue,
containing 20 mM DTT in the reduction step (15 min) and
25 mM iodoacetamide in the alkylation step (15 min). IPG strips
were run in the second dimension on 20620cm 12.5% SDS-
PAGE gels using a Protean II xi 2D Cell (Bio-Rad). Gels were run
in triplicate, silver-stained [78] and scanned (GS-710 Densitom-
eter, Bio-Rad) as gray-scale tiff files at 16 bit and 300 dpi and
uploaded into the Progenesis ‘SameSpots’ (Non Linear Dynamics)
gel image analysis Software. Quantitative analysis was based on
average gels created from three gel replicates. Spots in the treated
Figure 5. Schematic representation of cellular pathways displaying changes in gene transcription in response to linoleic acid
challenge conditions. Sections A, B, C and D highlight the various genes involved in peptidoglycan, carotenoid, menaquinone and energy
metabolism respectively. Genes in red and blue boxes are up- and down-regulated, respectively. See text for details.
doi:10.1371/journal.pone.0004344.g005
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sample were considered statistically significant. For protein
identification by mass spectrometry 2 gels containing 800 mg each
of soluble protein (a pool from each growth condition) were
prepared as above and stained with Colloidal Coomassie Brilliant
Blue [79]. The scanned images were uploaded into Progenesis
‘SameSpots’ and matched to the analytical gels.
Trypsin digestion and mass spectrometric identification
of proteins
Spots for identification were excised and digested in-gel with
trypsin. Gel Plugs were destained in 50% (v/v) acetonitrile:50%
(v/v) 50 mM ammonium bicarbonate (37uC), dehydrated in 100%
acetonitrile (37uC), and rehydrated overnight (37uC) in 10 mlo f
50mM ammonium bicarbonate containing trypsin (1 ml of 100 ng
Table 13. Strains and plasmids used in this study.
Strain or Plasmid Comment Reference or Source
Strains:
E. coli:
DH5a ø80 (lacZ)M15 (argF-lac)U169 endA1 recA1 hsdR17 (rK
2 mK
+) deoR thi-1 supE44 gyrA96 relA1 [86]
S. aureus:
SH1000 Functional rsbU derivative of 8325-4 rsbU
+ [87]
MRSA252 Wild-type clinical isolate [52]
RN4220 Restriction-deficient transformation recipient mutant of 8325-4 [88]
N315 Wild-type pharyngeal smear clinical isolate [89]
MSSA476 Wild-type clinical isolate [52]
Liv033 (katA) 8325-4 katA::Tn917 [87]
Liv038 (agr) SH1000 agr::tet [87]
Liv039 (sarA) SH1000 sarA::kan [87]
Liv101 (lytS) SH1000 lytS::pER1 [45]
Liv130 (sigB) SH1000 sigB::tet [87]
Liv142 (atl) SH1000 atl::lacZ pAZ106 [44]
Liv405 (clfA) 8325-4 clfA::lacZ pAZ106 T. Foster
Liv442 (clfA) SH1000 clfA trandsduced from Liv405 This Study
Liv671 (clpC) SH1000 clpC::erm [90]
Liv673 (crtM) Newman crtM::cat [91]
Liv681 (crtM) SH1000 crtM::cat transduced from Liv673 This study
Liv684 (sasF) RN4220 sasF::tet This Study
Liv686 (arcA) RN4220 arcA::tet This Study
Liv692 (arcA) SH1000 arcA::tet transduced from Liv686 This Study
Liv694 (sasF) SH1000 sasF::tet transduced from Liv684 This Study
Liv718 (vraS) SH1000 vraS::tet transduced from Liv723 This Study
Liv723 (vraS) RN4220 vraS::tet This Study
Liv750 (katA) SH1000 katA::Tn917 transduced from Liv033 This study
Liv753 (vraE) SH1000 SAR2782::Tn917 This Study
Liv766 (SAR2632) SH1000 SAR2632::Tn917 This Study
Liv994 RN4220 pSK5630+sasF This Study
Liv995 RN4220 pSK5630+arcA This Study
Liv996 RN4220 pSK5630+vraE This Study
Liv997 RN4220 pSK5630+SAR2632 This Study
Liv1000 (sasF) Liv694 complemented with pSK5630+sasF This Study
Liv1001 (arcA) Liv692 complemented with pSK5630+arcA This Study
Liv1002 (vraE) Liv753 complemented with pSK5630+vraE This Study
Liv1003 (SAR2632) Liv766 complemented with pSK5630+SAR2632 This Study
Plasmids:
pLTV1 Temperature-sensitive plasmid harbouring Tn917 [69]
pAZ106 Promoterless lacZ erm insertion vector [92]
pDG1513 pMTL22 derivative [tet
r] [73]
pSK5630 Low copy number E. coli-S. aureus shuttle vector [cm
r][ 7 5 ]
doi:10.1371/journal.pone.0004344.t013
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Supernatants containing the extracted peptides were removed and
analyzed by MALDI-TOF.
Peptide Mass Fingerprinting (PMF) was conducted on a reflectron
MALDI-TOF instrument (M@LDI;Waters-Micromass,UK ). Sam-
ples were mixed in a 1:1 ratio with a saturated solution of a cyano-4-
hydroxycinnamic acid ACN: water:TFA (50:49:1 (v/v/v)). The
acquired spectra were analysed using MassLynx v 4.0 (Waters-
Micromass,UK) and were all externally calibrated with a mixture of
peptides. For each sample, all acquired spectra were combined and
processed as follows using MassLynx v 4.0: smoothing, 26smooth
u s i n gaS a v i t z k yG o l a ym e t h o ds e ta t+/2 3 channels and
background subtraction using a polynomial of order 1 and 40%
below the curve in order to reduce background noise. To get accurate
mono isotopic peak data all processed spectra were centred using the
top 80% of each peak. Peak lists were generated using ProteinLynx,
part of MassLynx v 4.0. Monoisotopic peptide masses in the mass
range of 800–4000 Da were used in the database search. The
resulting peptide mass maps were used to interrogate S. aureus
MRSA252 sequences to generate statistically significant candidate
identifications using the MASCOT search engine (Matrix Science).
Searches were performed allowing for complete carbamidomethyla-
tion (alkylation) of cysteine residues, partial oxidation of methionine
residues, one missed cleavage and a mass error of 250 ppm.
Molecular Weight Search (MOWSE) scores [80], number of
matched ions, percent protein sequence coverage, and correlation
of gel region with predicted mass and pI were collectively considered
for each protein identification.
Cell surface hydrophobicity assays
Cell surface hydrophobicity of S. aureus strains was measured as
described previously [81]. Briefly, stationary-phase cells (18-h
cultures) grown in the presence or absence of 0.1 mM linoleic acid
were harvested, washed three times and resuspended to an OD440
of 0.5 in PBS. 3 ml aliquots of each of these bacterial suspensions
were vortexed for 1 min with 200 ml n-hexadecane (Sigma). After
15 min incubation to enable partitioning, 1 ml was removed from
the aqueous layer and the OD440 recorded. Cell surface
hydrophobicity was calculated as the percentage decrease in OD
as a result of cells partitioning into the hexadecane.
Cell Autolysis Assay
Cell autolysis rates were determined on cells exposed to linoleic
acid using an assay modified from that described by Blackman et
al. [82]. Briefly, cells were grown in 100 ml volumes of BHI to an
Table 14. Oligonucleotides used for the construction of
mutants.
Oligonucleotides Sequence (59 to 39)
sasF_BamHI CCACGGATCCGGTAGTGATGTTTTGG
sasF_NotI ATAACTGCGGCCGCTTGAAACGGTTTCCCTCG
sasF_KpnI CCGGTACCGTTATCACGACGCAATAAG
sasF_EcoRI ACATGAATTCAAACAAGGAGTTCGGAC
arcA_BamHI CCACGGATCCACAAGTAGTAGATATGTG
arcA_NotI ATAACTGCGGCCGCTTAATTGGACCATCTGTC
arcA_KpnI CCGGTACCGACACTTTCTAATCAAG
arcA_EcoRI ACATGAATTCTGCTTTGGTAAATCAC
vraS_BamHI CCACGGATCCGCATGCTAGCTGCATTTC
vraS_NotI ATAACTGCGGCCGCCATTTCATGATCATCCAC
vraS_KpnI CCGGTACCCAAGCTGTCATCTATGCATTC
vraS_EcoRI ACATGAATTCGCTGAAACATCTACTC
Tet_NotI ATAACTGCGGCCGCGGCGGATTTTATGACCGATGAAG
Tet_KpnI CCGGTACCTTAGAAATCCCTTTGAGAATGTTT
Complementation
Sar2725_SasF_For ACGCGTCGACTAATATGATGTTAGCGACATGG
Sar2725_SasF_Rev ACGCGGATCCAATGATGGACAATCTATTCATTGC
arcA_For ACGCGTCGACGTGAATATAATCACATGTAAGCG
arcA_Rev ACGCGGATCCTCTGTCATTATTTTCACCCTCG
Sar2632_For ACGCGTCGACTTTATAACTCGTAAATCAGTCTC
Sar2632_Rev ACGCGGATCCCATGTAAAATTTGCGACATTGC
Sar2782_vraE_For ACGCGTCGACTGTCATCATGCTAAAAGATGGC
Sar2782_vraE_Rev ACGCGGATCCAGTTAATAGTTATACTGCATTGC
doi:10.1371/journal.pone.0004344.t014
Table 15. Oligonucleotides used for qRT-PCR analysis.
Oligonucleotide SAR Number Sequence (59 to 39)
gyrB_For SAR0005 ATCGACTTCAGAGAGAGGTTTG
gyrB_Rev SAR0005 CCGTTATCCGTTACTTTAATCCA
spa_For SAR0114 GAAGCAACCAGCAAACCATGC
spa_Rev SAR0114 ACGTCCAGCTAATAACGCTGC
fadA_For SAR0223 GAAGATGTCATTGTTGGTACGG
fadA_Rev SAR0223 TGTAATCCTGATGAGCAGTAGC
fadD_For SAR0225 TTCATTGCTAGAAAGTAAGTACCG
fadD_Rev SAR0225 TGGCGTTTGGACGATCCTTGT
lytR_For SAR0258 TTTTTGCAACTGCACATGACCAA
lytR_Rev SAR0258 TTATCATCTTTGGCTTTAGTCGC
sarA_For SAR0625 TAAACTACAAACAACCACAAGTTG
sarA_Rev SAR0625 TTCGATTTTTTTACGTTGTTGTGC
clpB_For SAR0938 GAACGAGCAAATATTGAGGTAGA
clpB_Rev SAR0938 GCCTTAGTTATCAATTGGTTTGC
fabI_For SAR0978 GTGATGGGTGTTGCTAAAGCG
fabI_Rev SAR0978 AACCACCCACACCTTTTGCAC
hla_For SAR1136 GTTGCAACTACCTGATAATGAAG
hla_Rev SAR1136 CCAATTTTTCCAGAATCATCACC
katA_For SAR1344 AATAGTATGACAGCAGGGCCTA
katA_Rev SAR1344 AATGTCCCAAATGCACCAGAAC
murG_For SAR1430 ATCCCGAGGCGACCAAATTGA
murG_Rev SAR1430 AATTCGAGTTCTTTCCTGTTCCA
fabZ_For SAR2186 AATATGAAGAAGGTCAACGTTGC
fabZ_Rev SAR2186 ACCGCACCTGTTTGAGCTAACG
cidA_For SAR2621 GCCGGCAGTATTGTTGGTCTA
cidA_Rev SAR2621 TAATACCTACAACTGACGGTATG
crtM_For SAR2643 TGATGACAGTATAGATGTTTATGG
crtM_Rev SAR2643 ACATGCTGAAGGGCCATCATG
arcA_For SAR2714 GTCAGGAGTACGTAAGGAAGA
arcA_Rev SAR2714 GTGTCCTATTGAGGCTTGTGG
sasF-For SAR2725 CACAAATCGGAAGATTCAGC
sasF_Rev SAR2725 TGAGTCGATTACTATGGCTTTGA
RNAIII_For RNAIII ACATGGTTATTAAGTTGGGATGG
RNAIII_Rev RNAIII TAAAATGGATTATCGACACAGTGA
doi:10.1371/journal.pone.0004344.t015
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acid. Following harvesting of the cells by centrifugation, the cells
were washed in PBS and resuspended to an OD600=0.6 in 0.5%
(v/v) Triton X-100. The cells were incubated with shaking at 37uC
and the OD600 was monitored over time.
Experimental septic arthritis
A well described mouse model of septic arthritis was used to test
the in vivo role of genes implicated in resistance to fatty acids in the
strains [83–85]. Seven week old female NMRI mice were obtained
from Charles River Laboratories (Sulzfeld, Germany) and
maintained in the animal facility of the Department of
Rheumatology and Inflammation Research, University of Go ¨te-
borg, Sweden. All mice were maintained according to the local
ethic board animal husbandry standards. The mice were housed
10 to a cage under standard conditions of temperature and light
and were fed standard laboratory chow and water ad libitum.
Bacteria were grown on blood agar plates for 24 h, harvested and
stored frozen at 220uC in PBS containing 5% bovine serum
albumin and 10% dimethyl sulfoxide. Before injection into
animals, the bacterial suspensions were thawed, washed in PBS,
and adjusted to appropriate cell concentrations. Mice were
inoculated in the tail vein with 0.2 ml of bacterial suspension.
The number of viable bacteria was measured in conjunction with
each challenge by counting colonies following culture at 37uC for
24 hours on blood agar plates. Ten mice were infected with each
strain of S. aureus by i.v. injection in the tails of 3.2–3.5610
6 CFU
of bacteria for induction of septic arthritis. The mice were weighed
regularly and examined for arthritis until death by cervical
dislocation 14 days after challenge. The kidneys were aseptically
dissected and kept on ice, homogenized, diluted in PBS and
inoculated on blood agar plates. Data were presented as CFU per
kidney pair.
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